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Prions diseases affect numerous mammalian species and may arise spontaneously; 
from genetic predisposition of the prion protein, PrPC, to misfold and aggregate; or from 
contacted with prion-contaminated materials. The first described prion disease, scrapie, 
manifests in sheep, and records date back to the 18th century. Other mammalian 
species susceptible to prion diseases include humans, cats, mink, cervids (deer, elk, 
and moose), and cattle. The term Transmissible Spongiform Encephalopathy (TSE) 
arose to describe this new class of infectious diseases which exhibit spongiform 
degeneration in the central nervous system (CNS). TSEs are invariably fatal diseases, 
and only herd culling or breeding resistance mitigate disease spreading. However, 
chronic wasting disease (CWD) in cervids represents the first known TSE to occur in 
free-ranging wildlife, and the apparent facile spread demands strategies to halt its 
spread and prevent species eradication.   
 
Human prion disease characterization dates back to the 1920s. However, the bovine 
spongiform encephalopathy (BSE or mad cow disease) outbreak and subsequent 
transmission into a small number of humans in the 1980s and 90s pressed the need to 
understand the TSE agent. Many researchers since the 1960s postulated protein at 
least partially comprised the agent, but Stanley Prusiner provided the first
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experimental evidence of protein composition correlating with infectivity. Further, he 
coined the term proteinaceous particle, or prion. Follow-up research elegantly 
highlighted a host protein requisite to cause disease. Researchers now broadly accept 
the disease mechanism involves misfolded prions perverting the cellular prion protein to 
alter its conformation and join the highly stable prion aggregate. 
 
Upon peripheral exposure, most prion strains propagate in the lymphoreticular system 
prior to invading the CNS.  Many elegant studies reveal the Complement system 
promotes initial prion trafficking and propagation in spleen and lymph nodes because 
mice deficient in various Complement proteins or receptors exhibit delayed or no 
disease. Once in the LRS, many postulate prions retrogradely infect the brain via 
sympathetic nerve fibers and the spinal cord. Once in the brain, prions provoke 
astrogliosis, neurodegeneration, and invariable death.  
 
While prion researchers made great strides in characterizing TSEs within a short few 
decades, many fundamental questions remain unaddressed. For example: what 
additional host factors foster prion pathogenesis? What is the normal function of the 
properly-folded, cellular prion protein? Lastly, do prion binding partners provide 
therapeutic targets? Data presented in this dissertation highlight crucial roles for 
Complement regulatory protein Factor H and Complement receptor CD21 in scrapie 
pathogenesis, suggest C1q may strain-specifically impact prion disease, highlight PrPC 
as a crucial mediator in the adaptive immune system, and provide potential therapeutic 
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Historical relevance. The advent of bovine spongiform encephalopathy, AKA mad cow 
disease or BSE, and the subsequent transmission into a small number of humans (Hill 
et al. 1997) in the 1980s and ‘90s, respectively, generated a great need to characterize 
and decipher the disease etiology. Many researchers asserted the pathogen exhibited 
characteristics of a slow-acting virus, and the race to detect and sequence the virus 
ensued. However, it would take a heretical and highly controversial study from Stanley 
Prusiner’s laboratory to classify an entirely new class of infectious agent, which he 
termed proteinaceous particle, or prion.   
 
The first record of this unusual type of disease dates back to 1732 in Great Britain. 
Sheep and goats infected with this disease, termed scrapie, display odd behavioral 
signs, including blank stares and rubbing along fences until they scrape off their wool or 
hair. Other hallmark signs of scrapie include weight loss and ataxia, a clinical term for 
incoordination. Brain lesions indicative of spongiform encephalopathy were first 
described in 1898 (reviewed in Wang et al. 2015). 
 
Other animals, often in situations of captivity, may also succumb to this type of disease. 
For example, Wisconsin ranch-raised mink farmers first observed a neurological 
disease similar to scrapie in 1947 (Hartsough and Burger 1965). Cervids, including 
deer, reindeer, elk, and moose, can succumb to chronic wasting disease (CWD), named 
after the overt weight-loss phenotype. CWD gained much attention in the media due to 
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the following worrisome characteristics: 1) the first prion disease known to affect free-
ranging animals, 2) the rapid spread into several states in the Continental United States 
and 3) the appearance (or perhaps first detection) in reindeer and moose in 
Scandinavia in 2016 (Benestad et al. 2016). CWD spreading mechanisms and origin(s) 
remain largely unknown. Some propose CWD arose from a spontaneous case which 
infected other cervids via contact with contaminated plants or soil; others propose all 
prion diseases come from the first described prion disease, scrapie.   
 
Perhaps one of the most unique features of scrapie is environmental persistence. 
Georgsson et al. (2006) analyzed Icelandic records regarding scrapie recurrence after 
herd culling. One farmer culled his entire flock in 1982 and housed a different flock in a 
new building until 1998. Sixteen years after culling the old flock, the farmer transferred 
4-5 lambs into the former sheep house, and one lamb developed scrapie within two 
years. These worrisome data suggest the scrapie pathogen can persist in the 
environment for at least 16 years. Studies suggest scrapie persists in soil (Seidel et al. 
2007) or dust (Gough et al. 2015). CWD appears to persist in the environment as well. 
Wyckoff et al. (2016) reported CWD transmission into model organisms housed on soil 
naturally contaminated with CWD. Collectively, these data highlight scrapie and CWD 
environmental persistence and begin to unravel the difficulty in producing efficient 
mitigation strategies.  
 
Human prion diseases. Pathologists Creutzfeld and Jakob characterized a distinctive 
neurological disease in the early 1920s. As reviewed in Wolfgang (1968), Creutzfeldt 
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first described a 23 year-old woman with a neurological disease lasting 2.5 years. 
Postmortem examination showed previously undescribed alterations in subcortical 
nuclei and grey matter in the cerebral cortex. Jakob described three similar cases the 
following year and termed the disease “spastic pseudosclerosis” in 1923. The name 
was later changed to Cruetzfeldt-Jakob disease (CJD) after the two pathologists who 
initially described the disease. We now recognize CJD as a human prion disease, but 
researchers did not appreciate the parallels between CJD and the other animal prion 
disease for several decades. 
 
Humans prion diseases occur due to polymorphisms in the PRNP gene, from 
spontaneous misfolding and aggregation of the PRNP protein product, PrPC, from 
ingestion of prion-contaminated tissues, or from iatrogenic exposure in surgery or blood 
transfusions. To date, there are 3 known genetic prion diseases. While spontaneous 
Creutzfeld-Jakob disease (sCJD) remains an enigma, heterozygosity at PRNP codon 
129 appears to offer some resistance to both spontaneous and acquired CJD (Palmer 
et al. 1991; Saba and Booth 2013). Lastly, humans can acquire CJD via ingestion or 
medical practices involving prion-contaminated tissues/blood or instruments.  
 
Genetic prion diseases include: familial CJD, Gerstmann-Straussler-Scheinker (GSS) 
disease, and fatal familial insomnia (FFI). Several PRNP polymorphisms correlate with 
phenotypes associated with genetic prion diseases (Mastrianni 2014). Genotype-
phenotype correlations in familial CJD include: Asp178Asn concomitant with 129V; 
Val180Ile; Thr183Ala; Glu200Lys; Arg208His; Val210Ile; or Met232Arg. GSS variants 
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include Pro102Leu, Pro105Leu, Ala117Val, Tyr145Stop, Gln160Stop, Phe198Ser, and 
Gln217Arg. Only one polymorphism is associated with FFI: Asp178Asn concomitant 
with 129M. Clinical manifestations of genetic prion diseases include: dementia, 
autonomic disturbances (such as insomnia in FFI), chorea, and ataxia. Due to clinical 
manifestations overlapping with more common Alzheimer’s disease (AD), many prion 
disease cases are likely misdiagnosed as AD. Thus, genetic testing aids in identifying 
genetic prion disease, but not sporadic or acquired CJD. Post-mortem analyses confirm 
prion disease diagnoses, including spongiform degeneration, astrogliosis, and anti-PrP 
positive amyloid plaques.  
 
As the name implies, spontaneous CJD (sCJD) seems to occur spontaneously. While 
there are no known causative PRNP polymorphisms associated with sCJD, 
heterozygosity at codon 129 seems to protect individuals from developing sCJD. In 
other words, individuals homozygous at codon 129 for either Methionine (M) or Valine 
(V) develop sCJD more frequently than heterozygous individuals. While M or V at  
codon129 does not alter the structure or folding of PrPC (Hosszu et al. 2004), 
heterozygosity likely alters downstream misfolding mechanism. Perhaps homozygous 
individuals with 100% of PrPC containing identical structure are more prone to self-
associate. However, this remains largely unexplored. Purified PrP is prone to aggregate 
under acidic conditions (Swietnicki et al. 2000). Therefore, perhaps one could study 
whether a pure sample of PrP containing 129M or 129V spontaneously misfolds at a 




Humans may also acquire prion disease from ingesting prion-contaminated cattle 
tissues. As mentioned above, most widely accept variant CJD (vCJD) arose due to BSE 
entering the human food chain. Similarly to sCJD, the main genetic factor known to 
increase the risk of acquiring vCJD is homozygosity at codon 129. In fact, only one 
known vCJD case occurred in an individual heterozygous at codon 129 (Kaski et al. 
2009). Although entirely devastating to patients and families, the World Health 
Organization reported only 175 total vCJD cases in the United Kingdom and 49 cases in 
other countries by 2012. Similarly, Diack et al. (2014) reported 177 cases in the UK and 
51 cases from other countries (228 total). However, recent estimates indicate 1:2,000 
people in the UK carry vCJD prions in their appendix. Many prions exhibit 
lymphotropism prior to invading the central nervous system (CNS), and Hilton et al. 
(1998) reported prion immunoreactivity in appendix prior to clinical onset. Therefore, Gill 
et al. (2013) screened archived formalin-fixed, paraffin-embedded appendix samples. Of 
the 32,441 samples tested, 16 showed prion immunoreactivity. This study begs the 
question: does subclinical infection equate to eventual clinical disease? 
 
Other examples of human prion disease transmission involve medical procedures or 
ritualistic cannibalism.  Rudge et al. (2015) reported 77 cases of iatrogenic CJD after 
cadaver-dervied pituitary-derived growth hormone treatment. These patients received 
growth hormone during childhood, and the onset of clinical signs occurred at 43 years of 
age (mean). Further, three iatrogenic CJD cases occurred after patients received blood 
transfusions contaminated with vCJD prions (Llewelyn et al. 2004, Peden et al. 2004, 
and Dietz et al. 2007), and humans can iatrogenically acquire prions [likely] from dura 
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mater grafts (Thadani et al. 1988 and Kim et al. 2011). Lastly, the prion disease Kuru 
arose in the Fore tribe in Papau New Guinea due to ritualistic cannibalism of deceased 
loved ones (reviewed in Liberski 2013), and Hadlow noticed similarities between Kuru 
and scrapie in 1959. Similarly to spontaneous and variant CJD, heterozygosity of codon 
129 confers prolonged incubation times or resistance to Kuru (Mead et al. 2008).  
 
Proteinaceous infectious only. After the BSE and vCJD outbreaks, the race to discover 
the pathogen ensued. Carleton Gajdusek, one of the primary researchers involved in 
describing Kuru, argued the pathogen exhibited characteristics of a slow-acting virus 
(Gajdusek 1967; Gajdusek and Gibbs 1968). In fact, most scientists and clinicians 
believed the agent was viral until the 1980s, and the Gajdusek laboratory continued to 
label the CJD pathogen a virus up to one year prior to Prusiner’s Nobel Prize award 
(Kordek et al. 1996). 
 
Many researchers noted the scrapie agent resisted viral inactivation procedures, such 
as formalin fixation (Pattinson 1965). However, it took Stanley Prusiner’s highly 
controversial publication (Prusiner 1982) to experimentally show the scrapie agent not 
only required, but is comprised of, protein. Prusiner argued the scrapie agent (termed 
proteinaceous particle, or prion) is much smaller than a virus and resists most nucleic 
acid inactivating procedures, including ultraviolet irradiation and formalin fixation 
(Prusiner et al. 1981 and 1982). As mentioned previously, Prusiner’s work and receiving 
a Nobel Prize was highly controversial. First, the concept of a protein pathogen did not 
sit right with virologists, and Prusiner received public ridicule (described in Mallucci 
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2014). Secondly, Prusiner was not the first to describe the scrapie agent’s resistance to 
nucleic acid inactivation (Alper et a. 1967, among others). Lastly, Alper et al. proposed 
the scrapie agent replicates without nucleic acid in 1967, and the hypothesis of self-
replicating proteins derived from host machinery was first described by Griffith (1967). 
Prusiner (1982) cited Giffith’s 1967 article, attributing the origin of replicating protein 
hypothesis to Griffith. Despite this citation, many felt as though Prusiner “piggy-backed” 
on others’ theoretical breakthroughs. 
 
However, the first experimental evidence of infectious proteins did indeed come from 
Prusiner’s laboratory. In 1981, Prusiner et al. showed proteinase K (PK, 100 µg/mL for 2 
hours) treatment reduced scrapie infectivity, whereas RNase or DNase minimally 
impacted infectivity. At this time, Prusiner et al. concluded a protein at least partially 
comprised the scrapie agent. McKinley, Bolton, and Prusiner (1983) showed the amount 
of scrapie protein component, termed PrP, directly correlated with infectivity. 
Specifically, they reported reduced titer corresponding to increased PK digestion. In 
other words, mild protease digestion did not affect scrapie infectivity, but complete 
digestion with PK ablated infectivity. These data, along with the evidence showing 
nucleic acid inactivation did not reduce scrapie infectivity, compelled Prusiner to present 
a new mechanism of information transfer outside of the central dogma of biology (DNA -
> RNA -> protein). 
 
While Prusiner and Griffith both implicated the involvement of host protein(s) in scrapie 
pathogenesis, it wasn’t confirmed until Oesch et al. (1985) sequenced PrP 27-30 
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(named for the relative molecular weight after gel electrophoresis). Briefly, Oesch et al. 
purified prions and separated the fragments by high pressure liquid chromatography 
(HPLC). The sequence was obtained by gas-phase sequencing, and they determined 
RNA sequence by reverse translation. They then revealed the sequence was present in 
the hamster genome via southern blotting, and mRNA transcript was detected in both 
infected and non-infected brains via northern blotting. This seminal work provided the 
first experimental evidence that the host genome indeed encoded PrP (named in 
Prusiner 1982). It wasn’t until 1993 that Bueler et al. showed the dependence on host 
PrPC to generate prion disease. In summary, Prnp knockout (PrP KO) mice resisted 
disease when inoculated with scrapie prions. They rescued this effect by crossing PrP 
KO mice to express the Syrian hamster transgene, rendering the mice susceptible to 
hamster prions. This groundbreaking study highlighted the importance of a host protein 
in scrapie pathogenesis.  
 
Interestingly, PrP KO mice are able to develop humoral (antibody) responses against 
scrapie prions (Prusiner et al. 1993). This phenomenon is easily explained by the built-
in regulatory mechanism to prevent autoimmunity. During development, T and B 
lymphocytes which recognize host proteins are rendered anergic. While this mechanism 
prevents auto-immunity, this limits vaccination paradigms against prions since the 
disease relies on host protein expression. B cell-mediated humoral immune responses 
are either T- dependent or independent. T-dependent antigens require not only B cell 
antigen recognition, but also cognate T cell antigen recognition. In summary, B cells 
(and other antigen presenting cells) load peptides into MHC II complexes, and if T cells 
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simultaneously recognize antigens from the same pathogen via their T cell receptor 
(TCR), the B cell activates to produce antibody. However, antigens loaded into MHC II 
complexes are comprised of linear epitopes. Therefore, any T cell which recognizes a 
linear epitope from PrPC would be negatively selected against during development. 
Thus, the only hope to elicit an adaptive immune response against prions would arise 
from T-independent B cell activation. T-independent antigens are usually structural or 
repeating in nature. For example, lipopolysaccharide (LPS) from Escherichia coli is a 
repeating, polysaccharide structure which can elicit T-independent antibody responses.  
 
Perhaps vaccinating animals with prions in conjunction with a T-independent adjuvant, 
such as saponin (White et al. 1991) could aid in eliciting humoral immune responses 
against prions. However, vaccinating animals with prions raises the concern of infecting 
the animals with the vaccine. In fact, Gordon (1946) attempted to vaccinate animals with 
formalin-fixed scrapie prions, only to find all sheep succumbed to prion disease within 
two years. Future directions include determining a way to abolish prion infectivity yet 
maintain structural integrity. For more information regarding the complexities of prion 
vaccines, see Zabel and Avery (2015).  
 
Alternatively to vaccination, other antibody therapeutic options for combatting prion 
disease may exist. Perhaps vaccinating PrP KO mice with prions, then humanizing said 
antibodies, could provide a viable treatment. Further, Pardon et al. (2014) outlined a 
molecular biology technique to generate camelid “nanobodies” which share high 
homology with human variable domains. Nanobodies preferentially bind structural 
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epitopes, may spontaneously cross the blood brain barrier, and thus offer potential for 
treating prion disease. For more information, see Chapter 6. 
 
Prions and the immune system. While prions fail to elicit adaptive (B- or T- cell 
mediated) immunity, certain cells and proteins in the innate immune system recognize 
prions and counter-intuitively aid in initial spread and replication. Specifically, Michel et 
al. (2012) showed macrophages are the main cell-type to capture and/or retain prion 
rods in the peritoneal cavity and mediastinal lymph nodes. Once in the lymph node, 
cell:cell prion rod transfer occurs to B cells ~6 hours post-exposure. 
 
Several lines of evidence highlight a crucial role for follicular dendritic cells (FDCs) and 
B cells in prion disease pathogenesis. FDCs abundantly express PrPC, and limiting PrPC 
expression to FDCs alone sufficiently caused prion infection in spleen upon peripheral 
exposure (McCulloch et al. 2011). Further, juxtaposing FDCs to sympathetic nerve 
fibers in CXCR5-/- mice enhanced prion neuroinvasion (Prinz et al. 2003). Klein et al. 
(1997) showed B cell deficiency (µMT) prevented prion disease in a scrapie mouse 
model. Further, Mok et al. (2012) showed B cells distribute prions from draining lymph 
nodes to secondary lymphoid organs (SLOs) because specifically preventing B cell 
egress via sphingosine 1-phosphate receptor 1 deficiency prevented prion transport and 
propagation to SLOs. Intriguingly, however, PrPC expression on B cells is dispensable 
for establishing disease because PrPC deficiency specifically in B cells did not prevent 
neuroinvasion (Klein et al. 1998). These data suggest B cells utilize a mechanism 
beyond PrPC to capture and spread prions. Data presented within suggest Complement 
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Receptors 2/1 (CR2/1 or CD21/35) may be the putative peripheral prion receptor. For 
more information, see Chapter 3. 
 
Prions require an intact Complement system to establish disease because mice 
deficient in various Complement proteins either partially or entirely resist prion disease. 
Deficiency in C3, arguably the key player in Complement, causes a delay in prion 
accumulation and onset of clinical symptoms in CWD and scrapie mouse models 
(Michel et al. 2012b and Mabbott et al. 2001). Deficiency in the classical Complement 
cascade activator C1q also increases survival time in mouse model of scrapie (Mabbott 
et al. 2001). Dendritic cells (DCs) largely require C3 and C1q to capture and traffic 
prions to sites of replication because DCs from mice deficient in C1q or C3 capture 
fewer prions (Michel et al. 2012). Interestingly, Complement receptors CD21/35 
promote prion disease more-so than their endogenous ligand, C3. Mice deficient in 
CD21/35 display prolonged survival (Zabel et al. 2007) or entirely resist disease (Michel 
et al. 2012) in mouse models of scrapie or CWD, respectively, whereas transgenic mice 
lacking C3 eventually succumbed to disease. Collectively, these data highlight 
Complement’s critical role in prion disease pathogenesis, and suggest CD21/35 impact 
prion disease independent of C3. 
 
Glial cells in prion disease. Glial cells in the CNS include astrocytes, microglia, and 
oligodendrocytes. Astrocytes express PrPC and are thereby susceptible to prion 
infection. In fact, astrocyte-restricted PrPC is sufficient to cause infection after 
intracerebral inoculation (Raeber et al. 1997). Further, prion infection induces 
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astrogliosis, or the transition from quiescence to an inflammatory state. Several lines of 
evidence suggest neuroinflammation promotes neurodegeneration and eventual death. 
Kordek et al. (1996) reported mouse-adapted CJD infection induced ~200-fold TNF-
alpha increase in mice compared to non-infected controls. Astrocytes are known to 
produce TNF-alpha in response to various immunological stimuli (Chung and 
Benveniste 1990). Further, mice deficient in anti-inflammatory cytokine interleukin 10 
(IL-10) succumb to prion disease faster than IL-10 sufficient mice (Thackray et al. 
2004). IL-10 dampens the inflammatory response, and these data suggest IL-10 
prolongs survival during prion disease. Intriguingly, these effects were seen after both 
intracerebral and peripheral inoculation, suggesting IL-10 impacts both peripheral and 
CNS infection. Collectively, these data suggest neuroinflammation negatively impacts 
prion disease outcome, and perhaps promoting an anti-inflammatory state may prolong 
the life of a patient with prion disease.  
 
Microglia express PrPC (Brown et al. 1998) and likely also promote inflammation and 
subsequent neuronal death. Bate, Boshuizen, and Williams (2005) reported microglia 
induce neuronal death via a CD14-dependent mechanism. CD14 cooperatively signals 
with the LPS receptor, TLR4. Perplexingly, TLR4 mutant mice display accelerated prion 
disease onset regardless of inoculation route. These data suggest TLR4 signaling 
combats prion infection, yet also promotes neuronal cell-death via CD14. TLR4 and 
CD14 signaling in microglia appear to be a double-edged sword. Perhaps TLR4 
promotes prion phagocytosis by microglia, which helps remove prions, but the resulting 
inflammation, perhaps mediated by TNF-alpha (Wu et al. 2009), promotes neuronal cell 
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death. If so, perhaps future directions could include promoting TLR-mediated 
phagocytosis without the resulting cytokine response.  
 
Prion strains. Prions appear to undergo selection mechanisms and may display 
differential tropism and adaptation. While the concept of viral strains is intuitive based 
on differential genetic information and tropisms, the definition of prion strains remains 
murky. Prion strains exhibit distinct pathological phenotypes, but what “encodes” the 
differences between prion strains? For example, Bessen and Marsh (1992) reported 
transmissible mink encephalopathy (TME) inoculated into hamsters caused two distinct 
disease phenotypes after three passages. In one cohort, the hamsters displayed 
lymphotropism, hyperactive clinical signs, and succumbed to disease at 65 days 
(mean). The authors termed this phenotype hyper-TME (HY-TME). The hamsters in the 
second cohort did not display lymphotropism, exhibited lethargic behavior, and 
succumbed to disease at 168 days (mean). The authors termed this phenotype drowsy- 
TME (DY-TME)  
 
These data suggest prions may exist as different strains, but considering prions do not 
differ in primary sequence, does strain information exist at the conformational or post-
translational modification level? Do host factors preferentially select certain confomers 
within the milieu of original inoculum? Perhaps the answer may involve a combination of 
both. For example, the Caughey and Telling labs revealed differential conformational 
stabilities between different prion strains. Specifically, certain strains resist higher 
concentrations of guanidinium hydrochloride denaturation than others and show 
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differential antibody binding capacities (Saijo et al. 2016). However, Sjoberg et al. 
(2008) reported Factor H, a Complement regulatory protein, differentially binds prion 
confomers. Specifically, Factor H appeared to bind PrP oligomers to a greater extent 
than PrP fibrils. Thus, Factor H may bind certain confomers, and thus dictate which 
confomers evade Complement recognition and subsequent trafficking/propagation in 
vivo. For more information, see Chapter 2. In summary, prion strains remain enigmatic, 
although the selection mechanisms likely involve a combination of conformer stabilities 
and host selection mechanisms.  
 
Prion protein (PrPC) physiology. Human PRNP on chromosome 20 contains 3 exons. 
Exon 3 encodes the open reading frame (ORF) and thus protein product (See Figure 
1.1). Zahn et al. (2000) resolved the human prion protein NMR structure. The N-terminal 
domain contains copper-binding octapeptide repeats (Riek et al. 1996) and is largely 
flexible and disordered, while the globular, structured domain contains secondary alpha 
helices and anti-parallel beta sheet. The three alpha helices comprise residues 144-
154, 173-194, and 200-228. Residues 128-131 and 161-164 comprise the anti-parallel 
beta sheet.  The prion protein exists in three glycosylation states: diglycosylated, 
monoglycosylated, or un-glycosylated. N-linked glycan occupation occurs at asparagine 
residues 181 and 197 in humans (first described in Liao et al. 1986) or 180 and 196 in 
mouse (Locht et al. 1986). Riek et al. (1996) reported a disulfide bond between cysteine 
residues 179 and 214. Lastly, PrPC anchors to cholesterol-rich lipid raft domains via 




Figure 1.1. Structure of human PrPC. Human PRNP on chromosome 20 contains 3 
exons, and exon 3 encodes the ORF. The first 23 amino acids of PrPC (A, modeled from 
Acevedo-Morantes and Wille 2014) encode the signal sequence which is not found in 
fully processed protein. The octapeptide repeat region binds copper and other divalent 
cations. N-linked glycans may occupy Asn residues at 181 and 197 (red). PrPC anchors 
to the outer leaflet of the plasma membrane via glycosylphosphatidylinositol (GPI) 
addition on the C-terminus. NMR and crystal structures of human PrPC (B, from Hosszu 
et al. 2004) show that polymorphism at 129 (sphere) does not alter protein structure 
(129V: yellow; 129M: red; crystal structure: green). 
  
Mammals, from mice to men, abundantly express PrPC, and most notably in the 
lymphoid and nervous systems. However, the precise physiological function of PrPC 
remains elusive because Prnp-/- transgenic (PrP KO) mice appear to develop normally 
(Prusiner et al. 1993). However, PrP KO mice display deficiencies in long term 
potentiation during development (Caiati et al. 2013), and the Strittmatter group reports 
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synaptic signaling via the metabotropic glutamate receptor involves PrPC (Haas et al. 
2016). Further, PrPC promotes neurite outgrowth via interactions with neural cell 
adhesion molecule (NCAM) and Fyn kinase (Santuccione et al. 2005). These data 
suggest that while PrP KO mice appear to develop normally, PrPC may play a role in 
synaptic transmission. 
 
PrPC appears to potentiate T cell proliferation and/or immunological synapse formation 
between antigen presenting cells (APCs) and T cells. Specifically, Mabbott et al (1997) 
showed primary mouse lymphocyte proliferation in response to Con-A partially 
depended on PrPC because anti-PrP antibodies abrogated proliferation. Further, T cell 
mitogen PHA caused PrPC upregulation in human T cells, and T cell proliferation in 
response to anti-CD3 was abrogated by anti-PrP antibody 8H4 (Li et al. 2001). 
Cashman et al. (1990) also reported cell-activation increased surface levels of PrPC, 
and anti-PrP antibodies suppressed proliferation. However, antibody treatment could 
potentially disrupt cell:cell interactions necessary for stimulation. Interestingly, however, 
PrP-deficient dendritic cells (DCs) exhibited impaired PrP+/+ T cell stimulation, 
suggesting PrPC may exert its effect via APCs at the level of the immunological synapse 
(Ballerini et al. 2006).  
 
Several studies show PrPC regulation during cell stress/immunological responses. For 
example, Shyu et al. (2002) reported Prnp mRNA upregulation in response to heat 
shock. Interestingly, Lotscher et al. (2003) also reported increased PrPC 
immunodetection in germinal centers and follicular dendritic cell networks after vesicular 
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stomatitis viral infection. Ballerini et al. (2006) reported increased cell-surface PrPC in 
activated T cells, and inhibitory antibody SAF83 against PrP reduced proliferation after 
stimulation. Logic therefore serves to suggest PrPC plays a role in CD8+ cell signaling in 
response to an intracellular pathogen. However, Genoud et al. (2004) reported no 
deficiency in CD8+ T cell responses against cytotoxic lymphoctic choriomeningitis virus 
(LCMV) or vesicular stomatitis virus (VSV) in mice deficient in PrPC and its homolog 
Doppel. This was observed by LCMV-specific cytotoxic T lymphocyte numbers in blood, 
as well as antibody responses after vaccination. Collectively, these results suggest PrPC 
may participate in immunological events leading to lymphocyte activation, but the 
precise roles and functions remain unclear. 
 
B cells can generate humoral (antibody) responses both dependent and independent of 
T cell help. Lipopolysaccharide (LPS) is an example of a T-independent antigen due to 
repeating structures capable of activating B cells even without cognate T cell help. 
Interestingly, PrP KO mice show increased susceptibility to LPS-induced septic shock 
(Liu et al. 2015). Furthermore, PrPC cross-linking induced calcium flux and ERK 
phosphorylation in Jurkat T cells (Stuermer et al. 2004). Interestingly, ERK 
phosphorylation and calcium flux also occur in the process of B cell activation. Lastly, 
PrPC was found to co-precipitate with Fyn kinase (Shi et al. 2013), another known 
member involved in B cell activation downstream of antigen recognition. However, 
further biochemical experiments such as surface plasmon resonance are required to 
conclude this direct interaction. Collectively, PrPC appears to augment T cell 
proliferation, yet T-dependent immunological responses to viral infection do not appear 
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to depend on the expression PrPC (Genoud et al. 2004). Thus, the role of PrPC in an 
adaptive immune response remains unclear. Data generated in Chapter 5 aimed to 
address the role of PrPC in B cell activation. 
 
Physiologically-relevant prions. Not all protein aggregation associates with disease. In 
fact, protein aggregation appears to serves a biological across kingdoms. In bacteria, 
the Rho transcription terminator no longer halts transcription in its aggregated state 
(Yuan and Hochschild 2017). A similar phenomenon occurs in yeast cells, albeit through 
a different mechanism and involved protein (Wickner 1994, reviewed in Wickner et al. 
2007). These findings naturally incite various questions regarding misfolded proteins 
associated with disease. Do these proteins aggregate in response to the true culprit 
underpinning disease? In other words, could PrPC aggregation provide a biological 
signal, but occasionally becomes non-resolvable and infectious? One could easily test 
this hypothesis using techniques employed by yeast prion researchers. For example, 
semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) employs the use of 
partial denaturation with a detergent such as sodium dodecyl sulfate (SDS) to 
distinguish between soluble protein and higher-order aggregates. Perhaps PrPC 
aggregates in response to insult. Experiments to address this hypothesis are currently 
underway.  
 
Prion detection/diagnostics. Perhaps the largest hurdle in prion diagnostic involves 
discriminating prions from PrPC. Historically, researchers relied on prion resistance to 
protease digestion. Proteinase K (PK) digestion ranging between 10 – 100 µg/mL for 
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30-120 minutes digests PrPC but leaves the resistant prion core intact. This core 
fragment, termed PrPRES, is readily detected via western blotting and runs with apparent 
differences in molecular weight depending on BSE or CJD type (Hill et al. 1997 and 
Casalone et al. 2004). Further, prion histological detection relies on formic acid 
denaturation and/or PK digestion. Experiments from our laboratory suggest different 
prion strains, for example mouse-adapted scrapie vs transgenic CWD models, require 
different protocols for IHC detection and thus highlight stability differences between 
prion strains as discussed previously.  
 
The aforementioned techniques require relatively high prion loads for detection, and 
sub-threshold prion levels may go undetected and thus prone to type-II error. Therefore, 
Claudio Soto’s laboratory (Saborio et al. 2001) developed an amplification technique, 
termed protein misfolding cyclic amplification (PMCA), which provides substrate for sub-
threshold prion seeds to amplify in vitro. Briefly, PMCA employs the use of perfused 
brain homogenate derived from mice which over-express PrPC to amplify prions in a 
37°C sonicator water bath. Growing prion seeds undergo 24 hour rounds with 
sonication bursts every 30 minutes to break up the prion aggregate into smaller seeds. 
Samples undergo serial rounds after 1:2 dilution into fresh normal brain homogenate 
(NBH). Each round is assessed for PrPRES via traditional PK digestion and western 
blotting. The Zabel laboratory translated Soto’s PMCA protocol to detect CWD using 
NBH from transgenic mice which overexpress the elk prion protein (Meyerett et al. 
2008). Further, the Zabel laboratory designed a PMCA scoring paradigm which 
correlates round to positivity with initial prion load (Pulford et al. 2012) and offers a way 
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to run statistical analyses. In other words, tissues with higher prion loads will become 
positive via western blot at earlier rounds than tissues with lower initial prion loads.  
 
The Nishida laboratory developed another prion amplification technique (Atarashi et al. 
2011) termed real-time quaking induced conversion (RT-Quic). Unlike PMCA, RT-Quic 
uses soluble, recombinant PrP as the substrate for amplifying sub-threshold quantities 
of prion seed. To date, researchers used RT-Quic to amplify prions derived from 
cerebral spinal fluid (Atarshi et al. 2011), brain, urine, and feces (John et al. 2013). 
While one could argue PMCA is more sensitive due to serial amplifications, RT-Quic 
minimizes animal use and is less time-consuming.  
 
Prion-like diseases. Several host proteins present amyloid formation assocated with 
neurodegenerative diseases. For example, Alzheimer’s, Parkinson’s, and Huntington’s 
diseases all contain a protein-misfolding component. While each disease displays 
unique manifestations and associated amyloid-forming protein, Verma et al. (2015) 
proposed a unifying mechanism of protein-based information transfer. Specifically, a 
native host protein undergoes a conformational transition and self-aggregates. A small 
number of misfolded protein units comprise oligomers, whereas fibrils are much larger. 
Fibrils associate to form plaques, and plaque depositions are a hallmark characteristic 
of the aforementioned neurodegenerative diseases. However, whether the protein 
misfolding underlie disease manifestations or are simply correlated with the true cause 




In summary, prions may affect various mammalian species and require host protein 
expression to cause disease. While prion researchers made great strides in 
understanding this newly discovered mode of information transfer, several questions 
remain unaddressed. For example, what cellular factors promote prion disease? What is 
the physiological function of the cellular prion protein? Lastly, how can we treat the 
invariably fatal prion diseases? Data presented in this dissertation aimed to at least 
begin to address these questions and provide evidence of various therapeutic targets 
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CHAPTER 2 – COMPLEMENT REGULATORY PROTEIN FACTOR H 




Several Complement proteins and receptors exacerbate mouse models of prion 
disease, including C3, C1q, and CD21/35. These proteins of the Complement cascade 
likely increase uptake, trafficking, and retention of prions in the lymphoreticular system, 
hallmark sites of early PrPSc propagation. Complement regulatory protein Factor H (fH) 
binds post-translationally modified host proteins and lipids to prevent C3b deposition 
and thus autoimmune cell lysis. Previous reports show fH binds various conformations 
of the cellular prion protein, leading us to question the role of fH in prion disease. We 
report a biophysical interaction between purified fH and prion amyloid (“prion rods”) 
enriched from prion-diseased brain. Further, in a scrapie mouse model, we report 
transgenic mice lacking Cfh alleles unexpectedly resist prion accumulation and onset of 
terminal disease in a gene-dose manner. We conclude from these data and previous 
findings that the interplay between Complement and prions likely involves a complex 
balance of prion sequestration and destruction via local tissue macrophages, prion 
trafficking by B and dendritic cells within the lymphoreticular system, intranodal prion 
replication by B and Follicular Dendritic cells, and potential prion strain selection through 
Factor H.  Collectively, these findings shed new light onto the paradoxical role of 
Complement regulatory proteins in prion disease. 
																																																								
1 A version of this chapter was recently accepted: Kane, SJ et al. Complement 
Regulatory Protein Factor H is a Soluble Prion Receptor That Potentiates Peripheral 




Prions encipher and transmit pathogen information via structural conversion of the 
soluble, cellular prion protein, PrPC, to a misfolded and aggregated prion. Examples of 
prion diseases include Creutzfeldt-Jakob disease in humans; scrapie in sheep and 
goats; bovine spongiform encephalopathy (BSE) in cattle; chronic wasting disease 
(CWD) in deer, elk, and moose; and transmissible mink spongiform encephalopathy 
(TME) in mink. Hallmark clinical signs of prion diseases can include dementia, ataxia, 
and weight loss.  Neuropathological manifestations of prion disease include astrogliosis, 
spongiform degeneration, and prion amyloid deposition.  Many prion strains propagate 
in lymphoid tissues during a clinically silent carrier phase prior to neuroinvasion and 
clinical manifestations. Interestingly, BSE and Drowsy TME prion strains lack this 
phenotype, implicating an alternate route to the central nervous system independent of 
lymphoid propagation (Somerville et al. 1997; Bartz et al. 2005).  
 
The (in)ability of certain prions to breech species barriers, as well as distinct 
biochemical and pathological characteristics among prions derived from the same PrPC 
primary sequence (Bessen and Marsh 1992) suggest prions can exist as different 
strains or quasi-species. However, whether these prion strains arise from enhanced 
thermodynamic stability of certain conformations in the original inoculum, or host factors 
preferentially promote certain prion conformations, remains inconclusive. Interestingly, 
prions derived from spleen display broader species tropism when compared to prions 
from brain (Beringue et al. 2012).  These data highlight strain selection capacity within a 
single host and suggest certain host factors likely select for certain prion strains during 
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the transition between establishing infection in extraneural tissues to ultimate 
neuroinvasion. However, whether selection occurs at the protein conformational level, 
post-translational modification status, protein:protein interactions, or cell-type level, 
remains unknown.  
 
Several elegant studies implicate a branch of the innate immune system, Complement, 
as a facilitator of early prion spread and propagation. CD21/35- and PrPC-expressing 
follicular dendritic (FDC) and B cells capture pathogens opsonized with C3 and C4 
cleavage products and decrease the threshold to activate B cells to induce antibody 
production. Both FDCs and B cells promote prion disease (Klein et al. 1998; Brown et 
al. 1999; Montrasio et al. 2000, Klein et al. 2001; Zabel et al. 2007, McCulloch et al. 
2011) despite the failure of adaptive immunity against prions. Many studies suggest 
Complement promotes trafficking of infectious prions to cells expressing PrPC, a 
substrate for the growing prion aggregate, in lymphoid follicles.  Specifically, mice 
deficient in C3, C4, C1q, and Complement receptors CD21/35 accumulate less splenic 
prions early in disease and partially or completely resist terminal disease (Zabel et al. 
2007; Michel et al. 2012). 
 
Considering the largely nonspecific nature of the Complement cascade, hosts require 
regulatory mechanisms to prevent self-recognition and subsequent autoimmunity.  
Complement Regulatory protein Factor H (β1H globulin, CFH, or fH) prevents 
Complement activation on host tissues by binding sialic acids and polyanionic 
carbohydrates, such as glycosaminoglycan (GAG), which are largely absent on 
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pathogen surfaces. Although C3b marks virtually all cell surfaces in circulation, Factor H 
bound to host polyanionic carbohydrates mediates C3b inactivation through co-factor 
activity with Factor I, as well as limits activity of the C3 convertase, C3bBb (Carroll et al. 
2011). Not surprisingly, mutations or deficiency in Factor H lead to autoimmune 
diseases such as membranoproliferative glomerulonephritis, atypical hemolytic uremic 
syndrome and age-related macular degeneration (Pickering et al. 2002, Zipfel et al. 
2007; Hageman et al. 2005).  
 
Both PrPC and PrPSc contain sialic acid residues, and splenic PrPSc is more sialylated 
than brain PrPSc (Srivastava et al. 2015). Furthermore, Factor H binds various 
conformations of recombinant PrPC free of all post-translational modifications (PTMs), 
suggesting Factor H potentially impacts prion disease outcomes via direct interactions 
with PrPSc (Mitchell et al 2007; Sjöberg et al. 2008). We confirmed a direct interaction 
between fH and recombinant PrP using surface plasmon resonance (SPR; data not 
shown), and for the first time demonstrate Factor H interacts with prion amyloid 
enriched from prion-infected brain. Collectively, these previous findings led us to 
investigate the role of fH in a mouse model of scrapie.  
 
Inactivation of  the Cfh gene renders mice deficient in plasma C3 (Pickering et al. 2002 
and confirmed in serum of mice reported here; data not shown). Since C3 promotes 
prion disease (Mabbott et al. 2001; Michel et al. 2013), its absence in mice also lacking 
fH confounds the ability to assess the role of fH in prion pathogenesis. To ascertain the 
specific effect of Factor H deficiency, we peripherally inoculated mice with a high dose 
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of mouse-adapted scrapie which affects C3 knockout mice nearly identically to wild type 
mice (Klein et al. 2001).. Transgenic mice expressing zero, one, or two allelic copies of 
Factor H exhibited a gene-dose effect in early prion accumulation and onset of terminal 
disease after challenge with a high dose of RML5 prions. Knockout and hemizygous 
mice accumulated fewer splenic and brain prions at early time points and resisted the 
onset of terminal disease in comparison to their fH sufficient cohorts. Overall, these 
surprising data demonstrate fH may play a direct role in prion disease by promoting 




Materials and Methods 
Mice.  All mice were bred and maintained at Lab Animal Resources, accredited by the 
Association for Assessment and Accreditation of Lab Animal Care Internationaland 
approved on January 14, 2016 by the Institutional Animal Care and Use Committee at 
Colorado State University. Factor H knockout mice on the C57/Bl6 background were 
kindly provided by Dr. Joshua Thurman (University of Colorado – Denver). We crossed 
Cfh-/- mice to hemizygosity with C57/Bl6 wild type mice from Jackson Laboratories. 
Hemizygous breeders generated pups of various Cfh genotypes.  
 
Protocol ID: 09-1580A. We determined Cfh genotype from extracted tail clip DNA 
(Qiagen 69504) using the following primers: 5’ CTACAAATGCCGCCCTGGAT 3’ 
(mzBAP3), 5’ CTGCCAGCCTAAAGGACCC 3’ (mzBAP4r), 5’ 
GTAAAGGTCCTCCTCCAAGAG 3’ (fHReg200), and 5’ 
GGGGATCGGCAATAAAAAGAC 3’ (NEO). mzBAP3 and mzBAP4r primers were 
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designed using NCBI’s primer design website and blasted against the available 
C57BL/6 genome to ensure specificity. PCR conditions were as follows for 35 cycles: 
denaturation at 95°C, annealing at 55°C, and elongation at 72°C.  PCR products were 
resolved using agarose gel electrophoresis. Amplicons of 400 bp (fHReg200 and NEO) 
indicated the presence of a knockout allele, and amplicons of 451 bp (BAP3/4) indicated 
the presence of a wild type allele.  
 
Mouse inoculations and clinical sign scoring. Age- and sex- matched mice (n ≥ 6 per 
genotype) ranging from 6 weeks to 1 year received 100 µL of approximately 106 lethal 
dose50 units of mouse-adapted scrapie strain RML5 prions into the peritoneal cavity. 
Mice were monitored daily and sacrificed at the onset of terminal disease or specified 
timepoints. We employed a scoring system to assess the severity of disease, including: 
tail rigidity (0-2), akinesia (0-4), ataxia (0-4), tremors (0-4), and weight loss (0-2). Mice 
scored above 10 (total) or with a 4 or above in one category were euthanized via CO2 
inhalation replacing 20% of air per minute to effect.   
 
Tissue collection and analysis. After euthanasia, the following samples were collected 
and frozen or fixed in 4% formaldehyde in 1X PBS: serum, spleen (half fixed, half 
frozen), kidneys (one fixed, one frozen), tail clip, and brain (half fixed, half frozen). We 
assessed the presence of protease-resistant prions (PrPRES) in 10% (w/v) homogenate 
after proteinase K (Roche) digestion (10 µg/mL for spleen and 50 µg/mL for brain) and 
western blotting using anti-PrP monoclonal antibody BAR224 (Cayman) conjugated to 
horseradish peroxidase (HRP). Blots were developed using chemiiluminescent 
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substrates hydrogen peroxide and luminol for 5 minutes at room temperature and 
visualized using a GE digital imager and ImageQuant software. Tissues negative for 
PrPRES on western blots were subjected to serial protein misfolding cyclic amplification 
(PMCA; Saborio and Soto, 2001). Briefly, PMCA uses 10% normal brain homogenate in 
PMCA buffer (1X PBS, 1% Triton X-100, 4 mM EDTA and 150 mM NaCl) from PrPC 
over-expressing transgenic mice, strain TgA20, as substrate for amplification of 
previously undetectable prions. Twenty-five microliters of normal brain homogenate 
(NBH) and 25 µL 10% sample homogenate, underwent a 40 second pulse of sonication 
at ~150 watts, followed by a 30 minute incubation, and repeated for 24 hours (one 
round). Serial rounds were set up similarly, transferring 25 µL of the previous round’s 
sample to 25 µL of fresh NBH. Fresh positive controls of 0.05% RML5 prions served as 
positive control for each PMCA round. Each biological sample was run in at least 
technical duplicates, and round-to-positivity was determined by PK digestion and 
western blotting. Relative PMCA units were assigned as previously described (Pulford 
et al. 2012).  Non-amplified samples containing detectable PrPRES  via western blot 
were not subjected to PMCA. 
 
Prion rod preparation and surface plasmon resonance. Prion rods were enriched from 
infected brain as previously described (Michel et al. 2012, Safar et al. 1990).  Briefly, 
brains from animals infected with chronic wasting disease (E2), hyper- or drowsy- 
transmissible spongiform encephalopathies (HY- or DY-TME) were homogenized in 1X 
PBS to 10% (w/v) concentration. Sucrose (1.2 M) was added to 10 mL of clarified tissue 
to a final concentration of 165.5 mM, and samples were ultracentrifuged (100,000 x g) 
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for one hour at 4°C.  Pellets were resuspended to a final protein concentration of 5.0 
mg/mL in 1X TBS containing 2.0% Triton X-100 (TBST) and incubated on ice for 30 
minutes.  Samples were subjected to another round of ultracentrifugation for 20 minutes 
at 0°C, washed twice in 1X TBST, and twice with 1X TBS.  The pellets were then 
resuspended in 1X PBS containing 1% sarcosyl and protease inhibitor cocktail (Roche).  
Vortexed samples were incubated on a heated shaker at 37°C for two hours at 800 rpm.  
Samples were then gently overlayed on a 0.32 M sucrose in PMCA buffer 1 (PMCA 
buffer without Triton-X 100) cushion, ultracentrifuged for one hour at 4°C, and 
supernatants removed.  Pellets were resuspended in 2.3 M NaCl, 5% sarcosyl in 1X 
PBS, centrifuges at 13,000 x g, washed three times in 50 mM Tris 150 mM NaCl, and 
were either stored dry or suspended in PBS at -80°C.  The presence of PK resistant 
prion rods was confirmed by western blot. 
 
Highly enriched prion rods were coupled to CM-5 sensor chips outside of the instrument 
after generating the reference flow cells within the instrument by activating with 
EDC/NHS and deactivating with ethanolamine three to five times. The chip was then 
removed from the instrument and the gold chip disassembled from the cassette.  The 
entire surface was activated with 100 µL of EDC/NHS for 12 minutes.  A pellet of rods 
was resuspended in 100 µL of 10 mM sodium acetate pH 5.4, sonicated at 37°C for 40 
seconds, and incubated on the gold chip at room temperature for one hour.  The chip 
was then briefly rinsed with 1X PBS, and remaining active groups were deactivated with 
ethanolamine for 7 minutes.  Prior to use in interaction analyses, startup cycles of 50 
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mM sodium hydroxide served to remove any nonspecifically bound prion rods from the 
surface. 
 
All SPR experiments involved recombinant PrP (rPrP) or prion rod enriched from 
infected brain as the ligand coated to a CM5 Series S sensor chip, and commercially-
available Factor H (CompTech) as the analyte. Factor H was buffer exchanged in 
Amicon filter devices into 1X Running Buffer (50 mM Tris HCl, 150 mM NaCl, pH 7.42). 
The rPrP-coated chip was kindly provided by Dr. Hae-Eun Kang in the Telling lab. 
Briefly, flow cells were first activated with 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and 0.05 M N-hydroxysuccinimide (NHS) for seven 
minutes at 10 µL/min.  Amine coupling recombinant cervid or murine PrPC in 10 mM 
sodium acetate pH 5.5 was accomplished by flowing 20 µg/mL of ligand over the 
activated chip for seven minutes at 10 µL/min.  Excess activated groups were 
deactivated with 1 M ethanolamine HCl pH 8.5 for seven minutes at 10 µL/min.  
Reference flow cells, built-in negative controls for this system, underwent rounds of 
activation and deactivation without the addition of protein ligand.    
 
Cell culture prion infection. N2a mouse neuroblastoma cells were grown in RPMI 
medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. RML5 
infected brain homogenate was UV-sterilized prior to infecting cells. RML5 was pre-
incubated with PBS or fH (5 µg/mL final) for 25 minutes prior to infecting cells. N2a cells 
(passage 3) were seeded at 100,000 cells per well in a 12 well plate and infected with 
0.3% RML5 containing PBS or fH. Cells were grown at 37°C and 5% CO2 for 4 days. 
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Wells were rinsed 2X in 1X PBS, and cells were detached from the plate using 5 mM 
EDTA in 1X PBS for 10 minutes. Cell pellets were resuspended in 100 µL PMCA buffer 
containing 1% Triton X-100 and lysed on ice for 30 minutes. Lysates were assessed for 
PrPRES using traditional PK digestion and western blotting techniques. 
 
C3 ELISA. C3 in brain in serum was quantified in serum and brain using a 
commercially-available ELISA and confirmed via western blot. Briefly, heart stick 
samples were allowed to clot at room temperature for 10 minutes, centrifuged at 1,000 x 
g (3600 rpm) for ten minutes at 4°C, and serum was pipetted off and stored separately 
at -20 or -80°C. Serum and 10% brain homogenate were diluted 1:50,000 and 1:10, 
respectively, in provided diluent prior to ELISA. After interpolating absorbance values 
from the known standard curves, the concentrations were multiplied by the dilution 
factor.  
 
Statistical analyses. All statistical analyses were performed using GraphPad Prism 
software. One- or two- way ANOVAs were run to compare genotype, sex, or the 
interaction between these two variables. P-values < 0.05 were considered significantly 
different. In the terminal disease study, we observed one male outlier and subsequently 
removed this data point. Technical duplicates or triplicates from each biological replicate 







fH directly binds PrPC and prion amyloid. Previous reports indicate a molecular 
interaction between various conformations of recombinant PrP and fH, but whether fH 
binds in vivo-derived prion amyloid remained unknown. We performed a previously 
published protocol which removes soluble PrPC and highly enriches insoluble prion rods 
(Safar et al. 1990; Johnson et al. 2010; Michel et al. 2012). We then coupled these prion 
rods to a CM5 sensor chip and tested an interaction with fH as an analyte. Intriguingly, 
fH was shown to bind both HY- and DY- TME with similar affinities, despite their 
differential lymphotropism (Figure 2.1). These data may highlight a role for fH impacting 





Figure 2.1. Factor H directly interacts with prion amyloid. Prion rods were enriched 
from infected brain homogenate as previously described (A) and contain PK-resistant 
material (B). Surface plasmon resonance (SPR) analyses reveal that Complement 
component C3 opsonizes prion amyloid, but Factor H can bind prion amyloid with 
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similar affinities (D) and potentially protect from C3 opsonization. Factor H analyte 
concentrations tested include 0 (red), 5 (blue), 100 (magenta), 500 (teal), 1000 (gold), 
and 2000 (gray) nM. 
 
 
fH does not affect splenic prion loads at 30dpi. To assess the role of fH in early scrapie 
trafficking and lymphoid propagation, we intraperitoneally inoculated littermates of 
various Cfh genotypes (Figure 2.2 and 2.3) with 106 LD50 units of RML5 and assessed 
for prion loads in brain and spleens. Interestingly, prion loads did not differ between 
genotypes at 30dpi (Figure 2.4), suggesting trafficking and early stages of replication do 
not depend on Factor H. 
 
 
Figure 2.2. Example of fH mouse genotyping. Extracted DNA from tail clips were 















Tube Animal Genotype 
1 143471-1 +/+ 
2 143471-2 -/- 
3 143579-1 +/-  
4 143579-2 +/- 
5 143579-3 +/+ 









NEO primers (A, top panel) generated a 400bp amplicon in the presence of a knockout 
allele, and PCR reactions containing BAP3 and BAP4 primers (A, bottom panel) 
generated a 451bp amplicon in the presence of a wild type allele. Panel B summarizes 
the genotyping results in A, and C shows the relative proportions of genotypes in this 




Figure 2.3. Experimental design of fH gene-dose study. Hemizygous breeders 
generated wild type, hemizygous, or knockout littermates. After determining the 
genotypes via PCR, mice received mouse-adapted scrapie in their peritoneal cavity. 
Specifically, mice received 100 µL of 1% CD-1 brain homogenate infected with Rocky 
Mountain Laboratory mouse-adapted scrapie 5 (RML5) prions. Mice (n=5+ per 
genotype) were sacrificed at 30, 60, 90, and 120 days post inoculation (dpi), and splenic 
prion loads determined via protein misfolding cyclic amplification (PMCA). In a blind-to-
genotype study, mice were observed daily for clinical signs of prion disease and 
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Figure 2.4. Factor H wild type, hemizygous, and knockout mice do not differ in 
splenic prion loads at 30dpi. Mice (n=5+ per genotype) received 100 µL of 1% RML5 
and were sacrificed at 30dpi. Spleens (10% w/v) were subjected to serial rounds of 
PMCA in duplicate and analyzed via proteinase K (PK) digestion and western blot. 
Normal brain homogenate without PK digestion served as a control for western-blot 
transfer and band-shift after PK digestion. Example PMCA data (A) shows roughly 
equal genotype proportions positive for PK-resistant prions in their spleen at round E. 
Relative PMCA units (rpu) were assigned to each animal and analyzed as described 
previously (Pulford et al. 2012). One-way ANOVA analysis revealed no statistical 
difference among fH genotypes (p=0.4883).   
 
 
fH does affect splenic prion loads after 30dpi. Splenic load increases corresponded with 
increased Cfh gene dosage after 30dpi (Figure 2.10A). We found statistically significant 
differences between genotypes analyzed at 60dpi (Figure 2.5), 90dpi (Figure 2.6), and 
120dpi (Figure 2.7). However, knockout mice reached wild type and hemizygous levels 





















































Figure 2.5. Factor H hemizygous and knockout mice contain lower splenic prion 
loads at 60dpi. Mice (n=6+ per genotype) received 100 µL of 1% RML5 and were 
sacrificed at 60dpi. Spleens (10% w/v) were subjected to serial rounds of PMCA in 
duplicate and analyzed via proteinase K (PK) digestion and western blot. Normal brain 
homogenate without PK digestion served as a control for western-blot transfer and 
band-shift after PK digestion. Example PMCA data (A) shows a higher proportion of wild 
type mice as positive for PK-resistant prions in their spleen at round A (top panel), 
whereas hemizygous and knockout mice required additional rounds (bottom panel) of 
PMCA to detect prions, indicating a lower prion load. Relative PMCA units (rpu) were 
assigned to each animal and analyzed as described previously (Pulford et al. 2012). 
One-way ANOVA analysis revealed a statistically significant difference among fH 
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Figure 2.6. Factor H hemizygous and knockout mice contain lower splenic prion 
loads at 90dpi. Mice (n=6+ per genotype) received 100 µL of 1% RML5 and were 
sacrificed at 90dpi. Spleens (10% w/v) were first analyzed for PK-resistant prions in 
their spleen after 10 µg/mL PK digestion and western blotting (A).  Samples positive for 
PrPRES by straight western blotting were assigned 200 rpu, and negative samples were 
subjected to serial rounds of PMCA until positive by western blot (B). Example PMCA 
data (B) shows a higher proportion of wild type mice as positive for PK-resistant prions 
in their spleen at round A (top panel), whereas hemizygous and knockout mice required 
additional rounds (bottom panel) of PMCA to detect prions, indicating a lower prion load. 
One-way ANOVA analysis revealed a statistically significant difference among fH 
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Figure 2.7. Factor H knockout mice contain lower splenic prion loads at 120dpi. 
Mice (n=6+ per genotype) received 100 µL of 1% RML5 and were sacrificed at 120dpi. 
Spleens (10% w/v) were first analyzed for PK-resistant prions in their spleen after 10 
µg/mL PK digestion and western blotting (A).  Samples negative in A were subjected to 
serial rounds of PMCA until positive by western blot (B). Example PMCA data (B) shows 
a higher proportion of wild type mice as positive for PK-resistant prions in their spleen at 
round A (top panel), whereas hemizygous and knockout mice required additional rounds 
(bottom panel) of PMCA to detect prions, indicating a lower prion load. One-way 
ANOVA analysis revealed a statistically significant difference among fH genotypes 
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Figure 2.8. Factor H hemizygous and knockout mice contain similar splenic prion 
loads as wild type by 150dpi. Mice (n=6+ per genotype) received 100 µL of 1% RML5 
and were sacrificed at 90dpi. Spleens (10% w/v) were subjected to serial rounds of 
PMCA until positive by western blot. Example PMCA data (A) shows roughly equal 
proportions of mice positive for PK-resistant prions in their spleens at round A (top 
panel) and B (bottom panel). Relative PMCA units (rpu) were assigned to each animal, 
and one-way ANOVA analyses revealed no statistical differences.  
 
 
fH promotes prion neuroinvasion. To determine the temporal pattern of neuroinvasion in 
response to fH status, we assessed prion loads in brain at 90dpi,120dpi, and 150dpi 
using sPMCA. Similar to the trend observed in spleen, prion loads in brain 
corresponded to Cfh status after i.p. challenge (Figure 2.9). Interestingly, knockout mice 






















































Figure 2.9. Analysis of prion loads in brain at early time points. Mice (n=5+ per 
genotype) received 100 µL of 1% RML5 and were sacrificed at the indicated time points. 
PrPRES was not observable by straight western blotting at 120dpi (A), and tissues from 
150dpi underwent several freeze-thaws, so all brains were subjected to sPMCA. 
ANOVA analyses revealed significant differences among genotypes at 90dpi (p=0.0285) 
but not 120dpi (p=0.0902) or 150dpi (p=0.4411). However, unpaired T-test (one way) 
analyses of wild type vs knockout shows a significant difference at 120dpi (p=0.0269). 
 
 
Temporal characteristics of prion accumulation over time, and its dependence on fH. 
Wild type, fH sufficient mice contained increasing splenic prion loads over time until 
reaching a plateau phase by 90dpi (Figure 2.11). Hemizygous mice displayed a lag 
phase, yet reached prion loads similar to wild type by 120dpi. Knockout mice did not 
reach prion loads similar to hemizygous and wild until 150dpi. As observed in spleen, 
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reached wild type and hemizygous prion loads by 150dpi (Figure 2.11), and 
densitometric comparisons did not reveal a statistical difference in PrPRES western blot 
signal at 180dpi (Figure 2.10). 
 
 
Figure 2.10. Mice of all fH genotypes contain detectable PK-resistant prions in 
their brain by 180dpi. Mice (n=6+ per genotype) received 100 µL of 1% RML5 and 
were sacrificed at 180dpi. Brains (10% w/v) were subjected to PK digestion (50 µg/mL) 
and western blotting (A). Densitometric analysis via ImageJ revealed a trend, albeit not 













































Figure 2.11. Cumulative early time point data. Data from previous figures except 
spleen at 150dpi were combined in order to visualize the effect of fH in prion loads in 
brain and spleen over time. Note that samples positive by straight western blotting 
received a conservative amplification score of 200.  
 
 
Absence of fH delays clinical manifestations of terminal prion disease. In a blind-to-
genotype study, we challenged littermates with a single peritoneal dose of RML5 and 
monitored mice daily for onset of clinical disease (Figure 2.12). Prion loads were 
assessed in brain via western blot (data not shown), and histopathological examinations 
were performed via immunohistochemistry (Figure 2.13). Aligning with early 
accumulation studies, fH-/- mice resisted the onset of terminal prion disease, perhaps 























































Figure 2.12. Factor H knockout mice resist the onset of terminal disease longer 
than wild type or hemizygous littermates.  Mice (n=8+ per genotype) received 100 
µL of 1% RML5 and monitored daily for the onset of terminal disease while blinded to 
genotype. See Materials and Methods for clinical scoring paradigm. Log-rank (Mantel-
Cox) statistical test revealed a significant difference in the survival curves (A, p=0.0018). 
Interestingly, we observed significant difference between sexes, although this did not 




Figure 2.13. Histological brain examination from Factor H terminal disease study. 























Genotype Sex Strain Attack Rate Days ± sd 
fH +/+ 
M C57/Bl6 5/5 222 ± 14 
F C57/Bl6 5/5 207 ± 7 
fH +/- 
M C57/Bl6 9/9 222 ± 16 
F C57/Bl6 4/4 215 ± 8 
fH -/- 
M C57/Bl6 4/4 238 ± 13 
F C57/Bl6 4/4 221 ± 6 















acidic protein in hippocampus (B, bottom, 20X). These images reveal prion deposition 
and neuroinflammation in cerebellum.  Interestingly, knockout mice exhibited 
immunostaining indicative of intracellular inclusion body deposition (arrow). Scale bars 
indicate 20 µm (top) and 50 µm (bottom). 
 
 
Female mice succumb to prion infection after peripheral inoculation before males. We 
observed an unexpected sex difference in mice of all fH genotypes, although two-way 
ANOVA analyses suggest the sex difference does not depend on fH genotype. To 
ascertain whether the sex difference arose depending on route of inoculation, data 
generated from previous researchers in the Zabel lab were statistically analyzed. 
Interestingly, the sex difference was only observed after peripheral (i.p.) exposure, but 
not after inoculation into the brain (Figure 2.14).  
 
 
Figure 2.14. The RML5 sex difference depends on route of inoculation. TgA20 
mice received 1% RML5 either intraperitoneally (i.p., n=3+ per sex) or intracerebrally 
(i.c., n=5+ per sex), and were sacrificed at the onset of terminal disease. Log-rank 
(Mantel-Cox) statistically analyses revealed significant differences between sexes after 
i.p. inoculation (p=0.0158), but not after i.c. inoculation (p=0.2535). Data from i.p. 
inoculation data was kindly provided by Dana Hill. 
 
 
Factor H may select for certain prion strains. In an attempt to develop an in vitro assay 
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brain homogenate with purified mouse fH containing short consensus repeats (SCRs) 
15-20 prior to infecting cells. Intriguingly, western blot analyses reveal a slightly 
elevated proportion of di-glycosylated PrPRES in cells infected with RML5 pre-treated 
with fH (Figure 2.15). Furthermore, histological examination show fH-/- mice contained 
unique PrPRES staining. Nearly all wild type mice infected with RML5 exclusively 
contain diffuse prion deposits, but fH-/- mice contained both puncta and florid plaques 
indicative of a perhaps new prion strain (Figure 2.15D). 
 
 
Figure 2.15. Preliminary data: fH may select for certain prion strains. RML5 
infected brain homogenate (0.3%) was pre-treated with PBS or fH containing SCRs 15-
20 (5 µg/mL final) prior to infecting N2a cells (A-C). Cells were grown for 4 days and 
analyzed for PrPRES via western blotting. While not statistically significant, a slight trend 
was observed consistent with previous findings: fH promotes prion infection (C) and 












































observed in a subset of knockout mice (D, 20X), which differed from the typically diffuse 
RML5 deposition seen in wild type mice. 
 
 
C3 may confound the effects seen in this chapter. Transgenesis leading to Factor H 
deficiency also renders mice deficient in serum C3 (Pickering et al. 2002). We 
confirmed these findings (Figure 2.16B,D). Previous reports in our lab among others 
(Michel et al. 2013; Mabbott et al. 2001) highlight a critical role of C3 in promoting prion 
disease (Figure 2.16), which necessitated an experimental design which specifically 
addressed the role of Factor H in prion disease. Klein et al (2001) reported a high dose 
of RML5 prions causes disease in wild type mice nearly identically to C3 deficient mice. 
While we attempted to circumvent this issue, we cannot overlook the possibility of C3 as 




Figure 2.16. C3 may confound the Factor H study. Previous work in the Zabel 
laboratory (A, Michel et al. 2013) revealed C3 promotes prion disease because mice 
genetically or pharmacologically deficient in C3 survive longer than their C3-sufficient 
cohorts. To assess the effect of Factor H deficiency on C3 levels, western blotting (B) 
and ELISA (C-D) were used to compare levels of C3 in serum of prion-inoculated fH 
mice. Factor H knockout mice contained undetectable levels of C3 in their serum. 
However, we inoculated with a high dose of RML5 prions which affected mice 
regardless of C3 status (Klein et al. 2001). 
 
 
C3 promotes CWD infection after intracerebral challenge in transgenic mice. In an 
attempt to assess the role of C3 in brain pathology, and its potential confounding effects 
in the aforementioned Factor H study, we intracerebrally challenged transgenic mice 
which overexpress elk PrPC and are C3 deficient (Tg5037;C3-/-) and monitored signs of 
clinical disease. Survival rates were compared to data previously generated in our lab 









































































































significantly longer than C3-sufficient mice. Further, C3 was detected in the brains of 
infected mice from the above Factor H study via ELISA, but not on prion rods used for 
SPR experiments (Figure 2.1).  
 
 
Figure 2.17. C3 promotes prion pathogenesis in the central nervous system. To 
assess whether C3 promotes prion disease specifically in the brain, transgenic mice 
expressing cervid PrP with or without C3 were intracerebrally inoculated with 30 µL 1% 
CWD-infected brain homogenate (E2) and monitored for clinical signs. Mice deficient in 
C3 survived significantly longer than their C3-sufficient historical controls (A). C3 was 
detected in brains of prion-infected mice via ELISA (B), although Factor H knockout 






We investigated the influence of Complement regulatory protein Factor H in establishing 
prion infection after peripheral insult. We initially hypothesized fH directly binds prions 
and protects them from Complement recognition and thus impedes subsequent 
trafficking/propagation in the lymphoreticular system. While we show fH directly binds 
prions (Figure 2.1), the in vivo data show an opposite trend than expected. These 


























































findings may be explained by strain selection, enhanced stability, or enhanced retention 
due to a direct, biophysical relationship between prions and fH. Our data indeed show 
fH directly binds prions, yet counter-intuitively promotes splenic propagation, 
neuroinvasion, and terminal disease onset. While fH-/- mice eventually succumbed to 
prion disease, lymphotropism and subsequent neuroinvasion were impaired 
(Summarized in Figure 2.11).  
 
Interestingly, splenic prion burdens did not differ between genotypes at 30dpi. While we 
cannot conclude whether fH plays a role in the initial trafficking of prions to the LRS, 
these data suggest fH may stabilize prions or promote propagation once captured in the 
LRS. We previously showed fluorescent prion rods entering afferent lymphactics both 
cell- and non-cell- associated (Michel et al. 2012). These findings suggest prions could 
traffic to lymphoid tissues cell-autonomously, which supports prions trafficking to the 
lymphoreticular system independent of an intact Complement system and perhaps 
partially aided by soluble fH acting as a transport chaperone. Thus, we cannot ascertain 
the effect of fH in the early trafficking stage of disease from the data presented here. 
Future studies could include fH inoculum pre-treatment and assessing early cell-
mediated and cell-autonomous trafficking, as well as degradation. 
 
We can envision a number of roles for fH in directly promoting prion disease. As 
discussed above, fH could act as a soluble prion receptor and cell-autonomously shuttle 
prions to extraneural sites of prion replication. Alternatively, or even additionally, fH 
bound to PrPC-expressing cells could capture prions, bringing them to the vicinity of 
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PrPC molecules, which then misfold and join the growing prion aggregate. Furthermore, 
fH may bind certain prion conformations or PTM statuses, thereby selecting for certain 
strains to replicate in the LRS.  
 
Previous studies using mouse models of scrapie (Mabbott et al. 2001) and CWD 
(Michel et al. 2013) reveal that mice genetically or pharmacologically deficient in C3 
accumulate less prions and resist terminal disease longer than their C3-sufficient 
controls. Prion opsonization likely involves not only local degradation of prions by 
macrophages, but also trafficking to and subsequent propagation in the LRS, hallmark 
areas of early prion replication. Factor H deficiency results in increased C3 convertase 
formation and causes unregulated cleavage of C3 and downstream depletion of serum 
C3 (Pickering et al. 2002). However, Klein et al. (2001) reported no difference in 
progression to terminal prion disease in C3 deficient and wild type mice upon a high-
dose challenge. Here, we report a significant delayed onset to terminal prion disease 
upon high dose challenge  in mice lacking fH and, therefore C3, compared to wild type 
mice.  Thus, fH deficiency likely plays a more substantial role in prolonging survival than 
simply eliminating C3. However, C3 deficiency in Factor H deficient mice nevertheless 
presents a confounding variable which we cannot overlook. Indeed, we present 
evidence that C3 could promote neuropathological manifestations of prion disease 
because mice deficient in C3 resist CWD longer than C3-sufficient mice (Figure 2.17). 
 
Complement control proteins contain highly homologous series of 60-70 amino acids 
termed short consensus repeats (SCRs). SCRs recognize certain C3/C4 cleavage 
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products, and each Complement control protein elicits distinct downstream functions. 
For example, Complement receptors 2 (CR2 or CD21) recognize opsonized pathogens 
via its SCRs and reduce the threshold of B cell activation, whereas Factor H recognizes 
siaylated host products via its SCRs to prevent autoimmunity. In essence, these 
proteins stimulate opposing effects using highly homologous SCRs. Domain mapping 
studies reveal CD21 containing the first two SCRs as sufficient to recognize prion 
amyloid (data presented in Chapter 3). We therefore conclude CD21 is a cell-surface 
prion receptor utilized to propagate in lymphoid tissues prior to neuroinvasion. We 
propose fH is a both a soluble and cell-associated prion receptor and assists in prion 
disease similarly to CD21.  We therefore conclude SCRs on complement control 
proteins, such as CD21 and fH, bind prions either cell-mediated or cell-autonomously 
and promote lymphotropism and subsequent neuroinvasion. 
 
Sjoberg et al (2008) reported fH biochemically interacts with various confomers of PrP, 
but preferentially bound oligomeric species. Amyloid plaques, both in Alzheimer’s and 
prion diseases, appear to be relatively innocuous forms of the misfolded protein, 
whereas oligomeric species cause the cytotoxic features (Silveira et al. 2005). Perhaps 
oligomeric species, due to their smaller size and less amyloidogenic status, are more 
sensitive to protease or cell-mediated degradation. Factor H may bind, thereby protect, 
and shuttle protease-sensitive oligomers to extraneural sites of prion propagation and 
amyloid production. We are currently investigating the role of fH in prion stabilization 




Baskakov and colleagues convincingly demonstrated that sialylation status differs 
among prion strains (Katorcha et al. 2015), which could dictate fH binding. Katorcha et 
al. (2014) reported that PrPSc sialylation increased prion infectivity. PMCA-generated 
material derived from de-sialylated substrate did not infect wild type mice, whereas 
PMCA-generated material from fully sialylated substrate exhibited 100% attack rate. fH 
may bind sialylated PrPSc and facilitate disease, albeit through an unknown mechanism. 
Hepatocarcinoma cells utilize sialic acids to selectively adhere to SLOs (reviewed in 
Baskakov and Katorcha (2016). Perhaps sialylated prions infect SLOs via a similar 
mechanism. Accordingly, de-sialylated PMCA material was undetectable in spleen or 
brain after serial rounds of PMCA, indicative of either degradation or urinary or fecal 
secretion. Perhaps fH could explain both of these findings by binding sialic acid on both 
cancerous cells and prions, causing an evasion of cellular destruction and granting 
entry to lymphoid tissues.  
 
Factor H could also be involved in selecting different prion strains allowed to propagate 
in lymphoid organs by preferentially binding sialylated prions.  Although we show here 
that fH binds both lymphotropic and non-lymphotropic strains (Figure 2.1), their 
sialylation status is unknown. Factor H has also been shown to bind recombinant PrP 
free of post-translational modifications (Mitchell et al. 2007; Sjoberg et al. 2008), and 
therefore may dictate prion strain selection and disease outcomes independent of, or in 
addition to, sialylation status. Qualitative, histological examination revealed a higher 
proportion of fH-/- mice contained florid or intracellular prion deposition/accumulation 
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versus the typical, diffuse RML5 deposition in wild type mice (see Figures 2.13 and 
2.15), supporting the hypothesis fH is a key host factor in prion strain selection. 
 
Altogether, these data support a role for fH in peripheral prion disease pathogenesis by 
directly interacting with infectious prions and promoting lymphotropism and subsequent 
neuroinvasion. We propose Factor H selects for certain prion strains. Whether this 
selection occurs at the level of prion conformation; sialylation status; evasion of 
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CHAPTER 3 – RELATIVE IMPORTANCE OF COMPLEMENT RECEPTORS CD21/35 




Complement Receptors 1 and 2 (CR1/2 or CD35/CD21) recognize opsonized antigens 
and stimulate phagocytosis and humoral immunity, respectively. Transcripts from the 
mouse Cr2 gene undergo differential splicing to generate proteins with both shared and 
unique Complement binding capacities and cell-type expression. In mouse models, 
genetic depletion of Cr2 causes either a delay or complete prevention of prion disease. 
However, the relative importance of CD35 vs CD21 in promoting prion disease remains 
unknown. Data from this chapter suggest both proteins can biochemically serve as cell-
surface prion receptors. However, mice lacking CD21 resist prion disease, whereas 
mice lacking CD35 succumb to prion disease at the same rate as wild type and 
hemizygous mice. Further, CD21 knockout mice contained lower splenic prion loads 
than CD35 knockout mice at 30dpi. FACS analysis of PrPC and CD19, cell-surface 
proteins known to impact prion disease, revealed a drastic increase of splenic CD19 in 
mice lacking CD21. Accordingly, previous studies reveal accelerated prion disease in 
mice lacking CD19, suggesting CD19 may exert protective effects against prion 
disease. Altogether, data from this chapter suggest CD21 promotes prion disease more-
so than splice variant CD35.  
 
																																																								
2 A version of this manuscript will be published in mSphere (under Editorial review): 
Kane, SJ et al. (2017). Relative Impact of Complement Receptors CD21/35 (Cr2/1) On 




The Complement system consists of >30 serine proteases which serves three main 
functions: 1) create the membrane attack complex (MAC) on pathogen cell surfaces to 
provoke osmotic pressure-induced cell-lysis; 2) opsonize pathogens to trigger 
phagocytosis; and 3) reduce the threshold for B cell activation upon simultaneous 
engagement of B cell receptor and Complement receptor 2. While Complement 
activation involves a largely nonspecific recognition of proteins and lipids, it links the 
fast-acting innate immune system with the long-term, memory-producing, adaptive 
immune system. 
 
As mentioned in previous chapters, Complement facilitates the early spread and 
propagation of prions to and within the lymphoreticular system (LRS). Specifically, 
transgenesis leading to deficiency in Complement proteins C3, C4, C1q, or CD21/35 
causes a delay or complete prevention of prion accumulation and disease onset 
(Mabbott et al. 2001; Zabel et al. 2007; Michel et al. 2012; Michel et al. 2013). 
Interestingly, in a mouse model of CWD, genetic depletion of Complement Receptors 
CD21/35 (Michel et al. 2012) completely protected mice from infection, whereas 
depletion of the receptors’ ligand, C3, delayed, but did not entirely prevent, disease 
(Michel et al. 2013). These data strongly suggest CD21/35 impacts disease 
independently of its natural ligand, C3. 
 
Murine CD21/35 (AKA CR2/1) arise from differentially splicing Cr2 transcripts (Molina et 
al. 1990), whereas the human genome encodes for CD21 and CD35 in separate genes 
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(Kurtz et al. 1990). In mice, Cr2 on chromosome 1 encodes 26 exons (NCBI gene, 
Figure 3.1A). Both transcripts share the first exon encoding for the signal sequence, and 
splicing to exon 7 and 2 encodes for CD21 and CD35, respectively. As discussed in 
Chapter 1, Complement control proteins bind ligand via their short-consensus repeats 
(SCRs) which elicit various, sometimes opposing, downstream functions. CD21 
contains 15 SCRs and recognizes C3 cleavage products. CD35 contains an additional 6 
N-terminal SCRs (Figure 3.1B) which recognize C4 cleavage products (Molina et a. 
1990; Fingeroth et al. 1989; Kurtz et al. 1990). 
 
CD21 binds to all its known ligands, iC3b, C3d, C3dg, CD23, and Epstein Barr 
gp350/220 using the first two SCRs (Kovacs et al. 2010, reviewed in Hannan 2016), 
whereas CD35 binds C4b cleavage products in addition to CD21 ligands (Reilly et al. 
1994). Thus, any interaction with CD21 also occurs with CD35, yet CD35 uniquely binds 
certain ligands. Some cell-types express both Complement receptors, whereas certain 
cell types express only one or the other. Considering murine Cr2 encodes both CD21 
and CD35, it is difficult to ascertain cell-type specific expression. However, humans 
encode CD21 and CD35 on separate genes and exhibit cell-type specific expression. In 
human, CD35 expression serves to clear immune complex by providing a phagocytic 
signal for macrophages (Newman et al. 1985) and neutrophils (Changelian et al. 1985). 
CD21 expression on B cells provides a co-stimulatory signal to reduce the activation 
threshold upon engagement of B cell receptor with its specific antigen (Cherukuri et al. 
2001; Del Nagro et al. 2005; Barrington et al. 2009). Mice deficient in both CD21 and 
CD35 exhibit impairment in combatting bacteremia (Cunnion et al. 2004) and eliciting a 
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humoral immune response (Haas et al. 2002). However, whether these findings arise 
from CD35 or CD21 remain unknown. Considering the highly homologous nature 
between mouse and human Complement proteins, we hypothesize mouse CD21 and 
CD35 serve similar functions as human CD21 and CD35.  
Figure 3.1. Illustration of murine splice variants CD35 and CD21. Murine Cr2 
encodes 26 exons, and CD21 and CD35 share exon 1 (A). Transcripts encoding for 
CD21 splice exon 1 to exon 7, whereas CD35 contains intervening sequences (A). 
CD21 and CD35 both contain extracellular short consensus repeats, a transmembrane 
(TM) domain, and a short cytoplasmic tail (B). However, CD35 contains an additional 6 
N-terminal SCRs (B). Shared sequences and structures are indicated in purple, and red 
indicates components unique to CD35. 
 
Considering murine CD21 and CD35 arise from the same gene, the relative functions of 
each isoform remains largely unknown. However, Donius et al. (2013a,b) generated 
mice which specifically express only one isoform (termed CD21 KO or CD35 KO here). 
A 
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Therefore, these mice provide valuable tools to ascertain specific isoform and cell type 
specific functions. We aimed to address the relative importance of CD21 and CD35 in 
prion accumulation and disease onset. 
 
The interaction between the host’s immune system and prions may initially seem 
counter-intuitive. Prions require expression of a host protein, PrPC (Bueler et al. 1993; 
Pruisner et al. 1993), to cause disease.  However, immunomodulatory mechanisms 
during development ensure auto-reactive lymphocyte (B and T cell) quiescence. These 
mechanisms certainly evolved to prevent self-antigen recognition and downstream auto-
immunity. Therefore, questions in the field include: how could a host elicit an adaptive 
immune response to prions without causing autoimmunity, and if prions bypass adaptive 
immunity, what components of the host’s immune system do they use to spread and 




Materials and Methods 
Mice.  All mice were bred and maintained at Lab Animal Resources, accredited by the 
Association for Assessment and Accreditation of Lab Animal Care International and 
approved on January 14, 2016 by the Institutional Animal Care and Use Committee at 
Colorado State University (Protocol ID: 09-1580A). CD21 (CR2) or CD35 (CR1) specific 
knockout mice on the C57/Bl6 background were kindly provided by the Weis laboratory 
(University of Utah School of Medicine). We crossed the individual knockout mice to 
achieve hemizygosity.  
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Mouse inoculations and clinical sign scoring. Age- and sex- matched mice (n ≥ 6 per 
genotype) ranging from 6 weeks to 1 year intraperitoneally received 100 µL of 
approximately 106 lethal dose50 units of mouse-adapted scrapie strain RML5 prions. 
Mice were monitored daily and sacrificed at the onset of terminal disease or specified 
timepoints. We employed a scoring system to assess the severity of disease, including: 
tail rigidity (0-2), akinesia (0-4), ataxia (0-4), tremors (0-4), and weight loss (0-2). Mice 
scored above 10 (total) or with a 4 or above in one category were euthanized via CO2 
inhalation replacing 20% of air per minute to effect.   
 
Tissue collection and analysis. After euthanasia, the following samples were collected 
and frozen or fixed in 4% formaldehyde in 1X PBS: serum, spleen (half fixed, half 
frozen), kidneys (one fixed, one frozen), tail clip, and brain (half fixed, half frozen). We 
assessed the presence of protease-resistant prions (PrPRES) in 10% (w/v) homogenate 
after proteinase K (Roche) digestion (10 µg/mL for spleen and 50 µg/mL for brain) and 
western blotting using anti-PrP monoclonal antibody BAR224 (Cayman) conjugated to 
horseradish peroxidase (HRP). Blots were developed using chemiiluminescent 
substrates hydrogen peroxide and luminol for 5 minutes at room temperature and 
visualized using a GE digital imager and ImageQuant software. Tissues negative for 
PrPRES on western blots were subjected to serial protein misfolding cyclic amplification 
(PMCA; Saborio and Soto, 2001). Briefly, PMCA uses 10% normal brain homogenate in 
PMCA buffer (1X PBS, 1% Triton X-100, 4 mM EDTA and 150 mM NaCl) from PrPC 
over-expressing transgenic mice, strain TgA20, as substrate for amplification of 
previously undetectable prions. Twenty-five microliters of normal brain homogenate 
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(NBH) and 25 µL 10% sample homogenate, underwent a 40 second pulse of sonication 
at ~150 watts, followed by a 30 minute incubation, and repeated for 24 hours (one 
round). Serial rounds were set up similarly, transferring 25 µL of the previous round’s 
sample to 25 µL of fresh NBH. Each biological sample was run in at least technical 
duplicates, and round-to-positivity was determined by PK digestion and western blotting. 
Relative PMCA units were assigned as previously described (Pulford et al. 2012).  
 
Prion rod preparation and surface plasmon resonance. Prion rods were enriched from 
infected brain as previously described (Michel et al. 2012, Safar et al. 1990).  Briefly, 
brains from animals infected with chronic wasting disease (E2), hyper- or drowsy- 
transmissible spongiform encephalopathies (HY- or DY-TME) were homogenized in 1X 
PBS to 10% (w/v) concentration. Sucrose (1.2 M) was added to 10 mL of clarified tissue 
to a final concentration of 165.5 mM, and samples were ultracentrifuged (100,000 x g) 
for one hour at 4°C.  Pellets were resuspended to a final protein concentration of 5.0 
mg/mL in 1X TBS containing 2.0% Triton X-100 (TBST) and incubated on ice for 30 
minutes.  Samples were subjected to another round of ultracentrifugation for 20 minutes 
at 0°C, washed twice in 1X TBST, and twice with 1X TBS.  The pellets were then 
resuspended in 1X PBS containing 1% sarcosyl and protease inhibitor cocktail (Roche).  
Vortexed samples were incubated on a heated shaker at 37°C for two hours at 800 rpm.  
Samples were then gently overlayed on a 0.32 M sucrose in PMCA buffer 1 (PMCA 
buffer without Triton-X 100) cushion, ultracentrifuged for one hour at 4°C, and 
supernatants removed.  Pellets were resuspended in 2.3 M NaCl, 5% sarcosyl in 1X 
PBS, centrifuges at 13,000 x g, washed three times in 50 mM Tris 150 mM NaCl, and 
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were either stored dry or suspended in PBS at -80°C.  Presence of PK resistant prion 
rods were confirmed by western blot. 
 
Highly enriched prion rods were coupled to CM-5 sensor chips outside of the instrument 
after generating the reference flow cells within the instrument by activating with 
EDC/NHS and deactivating with ethanolamine three to five times. The chip was then 
removed from the instrument and the gold chip disassembled from the cassette.  The 
entire surface was activated with 100 µL of EDC/NHS for 12 minutes.  A pellet of rods 
was resuspended in 100 µL of 10 mM sodium acetate pH 5.4, sonicated at 37°C for 40 
seconds, and incubated on the gold chip at room temperature for one hour.  The chip 
was then briefly rinsed with 1X PBS, and remaining active groups were deactivated with 
ethanolamine for 7 minutes.  Prior to use in interaction analyses, a startup cycle of 50 
mM sodium hydroxide served to remove any nonspecifically bound prion rods from the 
surface. 
 
All SPR experiments involved recombinant PrP (rPrP) or prion rod enriched from 
infected brain as the ligand coated to a CM5 Series S sensor chip, and purified CD21 
containing SCR1-2 or SCR1-6 was kindly provided by Dr. Hannan from University of 
Colorado (Denver) School of Medicine. CD21 was buffer exchanged in Amicon filter 
devices into 1X Running Buffer (50 mM Tris HCl, 150 mM NaCl, pH 7.42). The rPrP-
coated chip was kindly provided by Dr. Hae-Eun Kang in the Telling lab. Briefly, flow 
cells were first activated with 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and 0.05 M N-hydroxysuccinimide (NHS) for seven minutes at 10 
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µL/min.  Amine coupling recombinant cervid or murine PrPC in 10 mM sodium acetate 
pH 5.5 was accomplished by flowing 20 µg/mL of ligand over the activated chip for 
seven minutes at 10 µL/min.  Excess activated groups were deactivated with 1 M 
ethanolamine HCl pH 8.5 for seven minutes at 10 µL/min.  Reference flow cells, built-in 
negative controls for this system, underwent rounds of activation and deactivation 
without the addition of protein ligand.    
 
Cell culture prion infection. N2a mouse neuroblastoma cells were grown in RPMI 
medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. RML5 
infected brain homogenate was UV-sterilized prior to infecting cells. RML5 was pre-
incubated with PBS or CD21 (SCR1-2; 5 µg/mL final) for 10-20 minutes prior to infecting 
cells. N2a cells were seeded at 100,000 cells per well in a 12 well plate and infected 
with 0.3% RML5 containing PBS or fH. Cells were grown at 37°C and 5% CO2 for 4 
days. Wells were rinsed 2X in 1X PBS, and cells were detached from the plate using 5 
mM EDTA in 1X PBS for 10 minutes. Cell pellets were resuspended in 100 µL PMCA 
buffer containing 1% Triton X-100 and lysed on ice for 30 minutes. Lysates were 
assessed for PrPRES using traditional PK digestion and western blotting techniques. 
 
Flow Cytometry (FACS). Fresh brain and spleens were harvested and processed to 
single-cell suspensions in 3 mL PBS. Briefly, tissues were passed through 40 µm mesh 
filters using sterile plungers and cold PBS washes. Cells were pelleted at 250 x g for 5 
minutes at 4°C, and the supernatant was discarded. Red blood cells (RBCs) were lysed 
in lysis buffer for 5 minutes, cells were pelleted as previous, and washed in FACS buffer 
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(1X PBS, 1% FBS, and 1 mM EDTA). Primary splenocytes or brain suspensions were 
blocked in 7% mouse serum and 1:50 Fc block (BD Pharmagin) for 20-60 minutes on 
ice. Antibody solutions (1:100 final) were added to cells and incubated in the dark for 
one hour on ice. Cells were washed by adding 1 mL FACS buffer to existing antibody 
solution. Cells were pelleted, supernatant removed, and resuspended in 1 mL FACS 
buffer for a total of 3 washes. 792 µL cell suspension was added to 8 µL of Propidium 
Iodide (SIGMA) immediately prior to data acquisition in a Cyan flow cytometer.  Cells 
were analyzed 500-1500 events per second. Unstained samples were analyzed first in 
order to set parameters to achieve a well-defined peak in the first fluorescent decade. 
 
FACS analysis in Flow-Jo. Cellular debris was gated off the Y- axis of forward and side 
scatter plots. PI-positive (dead) cells were also gated off. Fluorochrome-positive gates 
were set by setting a threshold of 1% in the unstained population. In other words, 
stained cells were considered positive if their fluorescent intensity was greater than 99% 
of the unstained population. Mean fluorescent intensity (MFI), as well as frequency of 
parent gate, values were imported into Excel and/or GraphPad Prism for analysis.  
 
Statistical analyses. All statistical analyses were performed using GraphPad Prism 
software. One-way ANOVAs were run to compare genotypes. P-values < 0.05 were 







CD21 and CD35 both bind prion amyloid. Previous reports indicate a crucial role for 
CD21/35 in prion disease, but whether due to a direct interaction remained unknown. 
We performed a previously published protocol which removes soluble PrPC and highly 
enriches insoluble prion rods (Safar et al. 1990; Michel et al. 2012; Johnson et al. 2010). 
We then coupled these prion rods to a CM5 sensor chip and tested an interaction with 
purified CD21 protein containing either SCR1-2 or SCR1-6. We also test interactions 
between CD21 and HY- or DY- TME and observed interactions with both (data not 
shown). We then tested whether inhibitory monoclonal antibody 171 (imAb 171), which 
binds and blocks interactions at SCR 1-2 (Kulik et al. 2011), inhibits the interaction 
between CD21 and prion rods. imAb 171 reduced, but did not completely eliminate, the 
interaction. These data suggest CD21/35 bind prion rods at least partially using the first 
two SCRs on CD21. It is important to note, however, that the first two SCRs on the 
CD21 molecular correspond to SCRs 7-8 on CD35. Whether additional binding occurs 




Figure 3.2. CD21 and CD35 both bind prion rods. Prion rods were enriched from elk 
brain infected with chronic wasting disease as previously described. Equimolar full 
length CD21, or protein containing the first two or first six SCRs on CD21, all bound 
prion rods (A). Addition of inhibitory monoclonal antibody 171 (imAb 171) at least 
partially reduced the interaction, although we also observed some nonspecific binding 
with imAb 171 alone (B). Kinetic analysis reveal a 16 nM dissocation constant (kD) 
between full-length CD21 and prion rods (C). Concentrations of CD21 (C) tested 
include: 0(bottom), 1, 2, 10, 20, 100, and 200 nM(top). These data suggest the 
prion:CD21/35 interaction at least partially occurs using the first two SCRs on CD21/35. 
 
Early splenic accumulation partially relies on CD21. We inoculated mice with RML5 
prions and assessed prion loads in spleen at 30dpi. Mice deficient in CD21 accumulated 
slightly fewer prions in their spleen than CD35 deficient mice (p=0.0459). However, 
when C57/Bl6 wild type 30dpi PMCA data (Chapter 2) was included in the analysis, 
ANOVA analysis revealed no significant differences between genotypes. However, wild 
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type mice were not inoculated on the same day as CD21 or CD35 deficient mice, so this 
data was excluded from Figure 3.3.   
 
 
Figure 3.3. CD21 promotes splenic accumulation at 30dpi. Mice deficient in either 
CD35 or CD21 (n=7/genotype) were inoculated with RML5 prions and sacrificed at 
30dpi. Spleens (10% w/v) were subjected to serial rounds of PMCA and analyzed for 
PrPRES via western blotting (A). Mice deficient in CD21 scored significantly lower than 
CD35 deficient mice (B, p=0.0459; one-tailed T-test).  
 
 
Terminal prion disease onset relies on CD21, not CD35. Previous data suggested CD21 
may promote initial trafficking to and propagation in spleen (Figure 3.3). To ascertain 
whether splice variant CD35 or CD21 promotes the onset of terminal prion disease, we 
inoculated mice with RML5 prions and monitored the time to disease onset. CD21 
deficient mice resisted disease significantly longer than wild type, CD35 deficient, or 



























































Figure 3.4. CD21-deficient mice resist terminal disease onset longer than wild 
type, hemizygous, or CD35-deficient mice. Mice (n>6 per genotype) were inoculated 
with a single dose of RML5 prions and monitored for the onset of terminal disease. Mice 
deficient in CD21 lived significantly longer than all other genotypes, which did not 
significantly differ from each other (A-C). Panel B shows mean and standard deviation, 
and C shows p-value comparisons per group (Log-rank Mantel-Cox). Western blotting 
analysis revealed all mice contained PrPRES at the onset of terminal disease (D).   
 
 
CD21 pre-treatment inhibits prion replication in vitro. Cell-surface CD21 promotes prion 
disease, leading us to question whether pre-incubating prions with soluble CD21 could 
serve to block the prion:CD21 interaction and thus infection. Pre-treating RML5-infected 
brain homogenate with CD21 led to decreased PrPRES signal compared to PBS-treated 
control (Figure 3.5). Interestingly, non-digested, CD21 pre-treated samples contained 
























wt hemi CD35 KO CD21 KO 
wt 0.9435 0.4682 0.0454* 
hemi 0.8551 0.0120* 






Days ± sd 
wt C57/Bl6 11/11 218 ± 16 
hemizygous C57/Bl6 8/8 215 ± 10 
CD35 KO  C57/Bl6 6/6 212 ± 14 

















whether CD21 caused a reduction of PrPC, or whether increased PrPRES contributed to 
the higher total PrP signal in PBS-treated samples. These data suggest soluble CD21 
could serve as a therapeutic, and future directions include testing whether these 
findings are translatable in vivo.   
 
 
Figure 3.5. Soluble CD21 may serve as a therapeutic. RML5-infected brain 
homogenate (0.33%) was pre-treated with either PBS or CD21 (5 µg/mL final) prior to 
infecting N2a cells. After culturing cells with treatment for 4 days, cells were harvested 
and analyzed for PrPRES and GAPDH as a loading control (A). Cells infected with CD21 
pre-treated inoculum contained significantly lower PrPRES densitometric signal than 
PBS-treated controls (B, unpaired one-way T-test, p=0.0182). 
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CD21/35 double knockout phenotype depends on CD21. Previous reports indicate lack 
of CD21/35 causes an increase in another member of the BCR, CD19 (Hasegawa et al. 
2001). As shown in Figure 3.6, FACS analysis of CD19 cell-surface levels reveal a 
~35% increase of CD19 in CD21 knockout mice when compared to wild type or CD35 
knockout mice. Importantly, CD35 KO mice did not significantly differ from wild type 
mice. CD19 deficiency is known to promote prion disease (von Poster-Klein et al. 2008). 
However, CD19 deficiency did not impact splenic prion titers, but rather juxtaposed 
sympathetic neurons to FDC networks and thus facilitated more rapid neuroinvasion. 
Other members of the Zabel laboratory analyzed nerve fiber positioning and showed 
CD21 deficiency perplexingly also juxtaposes sympathetic nerve fibers to FDC networks 
(data not shown).  
 
CD21 or CD35 deficiency does not alter PrPC levels in brain. Data from other chapters 
suggests PrPC and CD21/35 may be co-regulated. CD21 deficiency leading to PrPC 
deficiency could explain the increased survival time and reduced prion loads in CD21 
knockout mice. To ensure this putative co-regulation did not confound the effects 
described here, we analyzed PrP MFI, as well as relative proportion of PrPC+ cells in 
brain.  CD21 or CD35 deficient mice did not differ in the percentage of PrPC+ cells, nor 
MFI compared to wild type (Figure 3.7). These data suggest the CD21 effect cannot be 





Figure 3.6. CD19 alterations depend on CD21. Previous reports show ~30% increase 
in surface CD19 in CD21/35 double knockouts (Hasegawa et al. 2001 and Haas et al. 
2002), as well as exacerbated disease onset in CD19 knockout mice (von Poster-Klein 
et al. 2008). We aimed to determine whether this phenotype depended on CD21 or 
CD35 via FACS. Histograms of live cells show CD21 KO mice have higher fluorescent 





Figure 3.7. PrPC is not a confounding variable. We tested whether PrPC levels in 
brain depended on the presence of CD21 or CD35, and our results suggest no 
















































































































































Attempts to ascertain CD21/35 functions previously relied on Cr2 genetic manipulations 
which render mice deficient in both CD21 and CD35. However, Donius et al. (2013a,b) 
generated mice which express one splice variant or the other, allowing researchers to 
determine the relative importance of cell-types which uniquely express each splice 
variant. Therefore, these mice provide a powerful tool to ascertain not only splice variant 
roles, but also specific cell type roles. For example, CD35 on macrophages and 
neutrophils is generally thought to promote phagocytosis and immune complex 
clearance, whereas CD21 on follicular dendritic (FDC) and B cells is thought to help link 
the innate and adaptive immune systems. These mice offer the ability to challenge or 
confirm these proposed roles. 
 
The role of Complement Receptors in prion disease is well established. Mice deficient in 
CD21/35 exhibit delayed clinical disease when challenged with mouse-adapted scrapie 
prions (Zabel et al. 2007). Interestingly, transgenic mice expressing cervid PrPC 
concomitant with CD21/35 deficiency completely resist terminal disease when 
challenged with elk chronic wasting disease prions (Michel et al. 2012). These seminal 
papers highlight a crucial role in CD21/35 in prion disease, although the relative 
importance of each splice variant remained unknown. 
 
Data presented in this chapter suggest both variants derived from Cr2 transcripts can 
biochemically interact with prion amyloid (Figure 3.2). This finding supports the previous 
in vivo data and suggests CD21/35 are cell-surface prion receptors. Interestingly, in the 
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mouse model of chronic wasting disease, C3 deficient mice eventually succumbed to 
prion disease, whereas CD21/35 deficient mice entirely resisted disease (Michel et al. 
2013 and 2012). These findings highlight Complement Receptors CD21/35 as more 
critical than their endogenous ligand, C3. These data, along with the biochemical data 
presented in this chapter, suggest CD21/35 impacts prion disease by directly interacting 
with prions. CD21/35 likely exerts its effects along with C3 opsonization, although 
perhaps not crucially.  
 
CD21/35-expressing B cells and FDCs are known to impact prion disease. Interestingly, 
B cells likely promote prion trafficking, not replication, because deleting Prnp specifically 
in B cells did not inhibit prion disease (Klein et al. 1998). In other words, B cells promote 
prion disease independent of PrPC expression. We believe data presented here could 
explain these findings. Perhaps CD21, not PrPC, is the cellular factor on B cells which 
aids prion pathogenesis. Future directions to test this hypothesis could involve silencing 
CD21/35 specifically in B cells and assessing the impact on prion accumulation and 
disease onset. 
 
To date, known CD35 functions include inducing immune complex phagocytosis on 
neutrophils and macrophages (Newman et al. 1985; Changelian et al. 1985) and 
immune complex clearance. CD21, however, engages C3d/g opsonized pathogens and 
provides a co-stimulatory signal when a mature, naïve B cell encounters its specific 
antigen. Therefore, in conjunction with previous reports, our data confirm B cells’ 
importance in prion disease, which likely arise from the interaction of CD21:prions. 
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However, CD35 can also biochemically react with prions, but likely promote 
phagocytosis and destruction with macrophages, the only cell-type known to help 
resolve prion infection (Beringue et al. 2000).  
 
Alternatively, or perhaps additionally, CD19 on B cells may dictate prion pathogenesis. 
Previous reports indicate CD21/35 deficiency causes a 36% increase in splenic CD19 
(Hasegawa et al. 2001; Haas et al. 2002), and we found this effect to mostly rely on the 
lack of CD21 (Figure 3.6A). CD19 deficiency causes prion disease exacerbation (von 
Poser-Klein et al. 2008). Reason would serve to suggest CD19 over-expression may 
inhibit disease, although this prediction has not yet been tested. However, CD19 
deficiency promoted neuroinvasion, not splenic accumulation or replication because 
splenic prion titers did not differ in wild type vs CD19 deficient mice at 90dpi. Rather, 
histological examination revealed CD19 deficiency led to dopaminergic nerve fiber 
positioning closer to FDC networks. This data suggests CD19 deficiency promotes 
neuroinvasion, not splenic accumulation or replication, by positioning nerve fibers closer 
to prion-replicating germinal centers. In contrast, data presented in this chapter suggest 
CD21 promotes splenic accumulation and/or replication (Figure 3.3), suggesting CD21 
promotes prion disease independently of CD19 alterations. In fact, other members in 
the Zabel laboratory showed increased nerve fiber juxtaposition in CD21 KO mice. 





Collectively, data presented in this chapter highlight a crucial role for CD21, not CD35, 
in prion disease. While CD21 and CD35 arise from the same gene in mice, and genetic 
deficiency in both isoforms protects or entirely prevents prion disease in mice (Zabel et 
al. 2007; Michel et al. 2012), the relative importance of each splice variant remained 
unknown. CD21 and CD35 exhibit cell-type specific expression, some of which promote 
prion disease (B cells), and some of which help resolve prion disease (Macrophages). 
While our SPR data suggests shared SCRs on both proteins can directly bind prions 
(Figure 3.1), we propose CD21-expressing cell types promote prion trafficking and 
replication moreso than CD35-expressing cell types because CD21 deficient mice 
contained less prion burden in spleen at 30dpi and resist the onset of terminal disease 
(Figure 3.3 and 3.4). Further, soluble CD21 may serve as a prion disease therapeutic 
(Figure 3.5), likely by preventing the prion:PrPC interaction. Future directions include 
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CHAPTER 4 – CLASSICAL COMPLEMENT ACTIVATOR C1Q MAY IMPACT PRION 




As discussed in previous chapters, Complement exacerbates prion disease. Previous 
reports illustrate C1q, a potent Classical Complement cascade activator, promotes 
scrapie pathogenesis. However, whether C1q impacts chronic wasting disease (CWD) 
remains unknown. In a CWD transgenic mouse model, we report mice which express 
elk PrPC and lack C1q paradoxically accumulate more prions and succumb to prion 
disease at a faster rate than C1q-sufficient mice. These findings are in direct opposition 
to expected outcomes based on previous literature.  However, we conclude C1q does 
directly impact prion disease because we observe a biophysical interaction between 
C1q and prion amyloid rods enriched from infected brain. Perplexingly, we found C1q to 
bind multiple strains of prion rods, suggesting C1q does not exert strain selection via 
simply binding or not. Future directions could include testing whether C1q causes 
differential Complement opsonization on certain prion strains or whether C1q 
preferentially binds certain PrPSc confomers. We conclude C1q impacts prion disease 
via strain selection mechanisms, although the precise mechanism remains unknown. 
Further, we propose repeating all experiments presented in this chapter due to a 
combination of human error and comparing new data to previously generated data. 






The Complement cascade involves a proteolytic cascade which functions to help the 
host clear cellular debris and microorganisms. The three main Complement functions 
include: opsonize (“tag”) structures for destruction via phagocytes; form the membrane 
attack complex to promote cell-lysis; and promote humoral immunity. While 
Complement consists of mostly nonspecific, fast-acting cascades, it plays a crucial role 
in eliciting a long-term, memory-producing, antibody response. For example, when a 
mature, naïve B cell encounters its antigen via membrane-bound IgM, stimultaneous 
Complement recognition and CD21 engagement reduces the activation threshold. 
 
While the immune system generally clears the body from foreign invaders and aberrant 
cells (ie cancer), certain pathogens use the immune system in order cause disease. For 
example, human immunodeficiency virus (HIV) infects certain cells of the immune 
system in order to replicate and spread disease. Many prion strains also hijack the 
normal, physiological function of the immune system in order to spread and propagate. 
Various Complement proteins and receptors promote prion disease because transgenic 
mice lacking C3, C1q, or CD21/35 exhibit delayed or entire prevention of prion disease 
(Mabbott et al. 2001; Michel et al. 2013; Michel et al. 2012).  
 
The C1q complex consists of 18 polypeptides arising from 3 subunits: C1qa, C1qb, and 
C1qc. Each subunit is encoded from a separate gene on chromosome 1, and six 
peptides of each subunit come together to form the 400 kD C1q complex. Each peptide 
contains collagen-like stalk near the N-terminus and a globular C-terminal domain. Bally 
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et al. (2013) likens the C1q complex to a bouquet of flowers. The collagen stalk 
domains associate to form the stem bundle, and the globular domains extend outward 
like the flowers. C1q recognizes IgM or dimeric IgG bound to pathogen using the 
globular domains. 
 
C1q is both a pattern recognition receptor (Jiang et al. 2015) and a potent classical 
Complement cascade activator. C1q recognizes immune complexes and stimulates the 
classical Complement pathway. C1q bound to immunoglobulin recruits calcium-
dependent C1s and C1r tetramer. This 790,000 kD multimolecular, complex, termed C1, 
recruits a series of proteins to form the C3 convertase, C4bC2a. Cleaved C3b joins the 
convertase to form the C5 convertase. This stimulates the terminal phase to form the 
membrane attack complex. The downstream effects of C1q recognizing immune 
complex includes phagocytic cell recruitment, as well as pathogen cell lysis. 
 
Several lines of evidence suggest C1q promotes synapse loss seen in 
neurodegenerative conditions. Silverman et al. (2016) showed C1q upregulation in wild 
type mice brain after CNS insult. Interestingly, C1q promotes neuronal loss because 
C1qa mice were protected against retinal ganglion cell loss and microglia activation. 
Further, Hong et al. (2016) showed C1q upregulation prior to synapse loss and plaque 
deposits in transgenic J20 brains which over-express human APP associated with 
familial Alzheimer’s Disease (Mucke et al. 2000). Hong et al. (2016) provide evidence 
that C1q directly responds to amyloid beta oligomers in early stages of AD. Oligomers 
led to C1q elevation and subsequent microglia activation in wild type mice, whereas 
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C1qa knockout mice exhibited less microglia activation and synapse loss after amyloid 
beta treatment. Therefore, C1q appears to promote neurodegeneration after injury and 
during disease. 
 
Previous reports highlight a role for C1q in scrapie pathogenesis (Mabbott et al. 2001). 
Whether C1q impacts other prion diseases such as chronic wasting disease (CWD), 
bovine spongiform encephalopathy, transmissible mink encephalopathy (TME), etc, 
remains unknown. Previous reports suggest C1q binds a conformationally modified form 
of recombinant PrP (Blanquet-Grossard et al. 2005). Therefore, we hypothesize C1q 
directly binds prions (and other plaque-forming proteins) and promotes initial trafficking, 
retention, and propagation of prions. Data presented in this chapter aimed to address 
the role of C1q in CWD. However, a combination of human error and comparisons 




Materials and Methods 
Mice.  Protocol ID: 09-1580A. All mice were bred and maintained at Lab Animal 
Resources, accredited by the Association for Assessment and Accreditation of Lab 
Animal Care Internationaland approved on January 14, 2016 by the Institutional Animal 
Care and Use Committee at Colorado State University. We bred mice of various C1q 
genotypes to knockout or hemizygosity status. We determined C1q and Prnp genotype 
from extracted tail clip DNA (Qiagen 69504) using previously published primers and 
PCR conditions. Transgenic mice expressing elk PrPC (Tg5037) were kindly provided by 
the Telling lab. 
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Mouse inoculations and clinical sign scoring. Age- and sex- matched mice (n ≥ 5 per 
genotype) received 100 µL of 1% (w/v) CWD elk isolate (E2) brain homogenate in the 
peritoneal cavity. Mice were sacrificed at specific time points or prior terminal prion 
disease onset. Mice were monitored daily and sacrificed at the onset of terminal disease 
or specified timepoints. We employed a scoring system to assess the severity of 
disease, including: tail rigidity (0-2), akinesia (0-4), ataxia (0-4), tremors (0-4), and 
weight loss (0-2). Mice scored above 10 (total) or with a 4 or above in one category 
were euthanized via CO2 inhalation replacing 20% of air per minute to effect.   
 
Tissue collection and analysis. After euthanasia, the following samples were collected 
and frozen or fixed in 4% formaldehyde in 1X PBS: serum, spleen (half fixed, half 
frozen), kidneys (one fixed, one frozen), tail clip, and brain (half fixed, half frozen). We 
assessed the presence of protease-resistant prions (PrPRES) in 10% (w/v) homogenate 
after proteinase K (Roche) digestion (10 µg/mL for spleen and 50 µg/mL for brain) and 
western blotting using anti-PrP monoclonal antibody BAR224 (Cayman) conjugated to 
horseradish peroxidase (HRP). Blots were developed using chemiiluminescent 
substrates hydrogen peroxide and luminol for 5 minutes at room temperature and 
visualized using a GE digital imager and ImageQuant software. Tissues negative for 
PrPRES on western blots were subjected to serial protein misfolding cyclic amplification 
(PMCA; Saborio and Soto, 2001). Briefly, PMCA uses 10% normal brain homogenate in 
PMCA buffer (1X PBS, 1% Triton X-100, 4 mM EDTA and 150 mM NaCl) from PrPC 
over-expressing transgenic mice, strain Tg5037 (Telling laboratory), as substrate for 
amplification of previously undetectable prions. Twenty-five microliters of normal brain 
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homogenate (NBH) and 25 µL 10% sample homogenate, underwent a 40 second pulse 
of sonication at ~150 watts, followed by a 30 minute incubation, and repeated for 24 
hours (one round). Serial rounds were set up similarly, transferring 25 µL of the previous 
round’s sample to 25 µL of fresh NBH. Each biological sample was run in at least 
technical duplicates, and round-to-positivity was determined by PK digestion and 
western blotting. Relative PMCA units were assigned as previously described (Pulford 
et al. 2012).   
 
Prion rod preparation and surface plasmon resonance. Prion rods were enriched from 
infected brain as previously described (Safar et al. 1990; Michel et al. 2012).  Briefly, 
brains from animals infected with chronic wasting disease (E2), hyper- or drowsy- 
transmissible spongiform encephalopathies (HY- or DY-TME) were homogenized in 1X 
PBS to 10% (w/v) concentration. Sucrose (1.2 M) was added to 10 mL of clarified tissue 
to a final concentration of 165.5 mM, and samples were ultracentrifuged (100,000 x g) 
for one hour at 4°C.  Pellets were resuspended to a final protein concentration of 5.0 
mg/mL in 1X TBS containing 2.0% Triton X-100 (TBST) and incubated on ice for 30 
minutes.  Samples were subjected to another round of ultracentrifugation for 20 minutes 
at 0°C, washed twice in 1X TBST, and twice with 1X TBS.  The pellets were then 
resuspended in 1X PBS containing 1% sarcosyl and protease inhibitor cocktail (Roche).  
Vortexed samples were incubated on a heated shaker at 37°C for two hours at 800 rpm.  
Samples were then gently overlayed on a 0.32 M sucrose in PMCA buffer 1 (PMCA 
buffer without Triton-X 100) cushion, ultracentrifuged for one hour at 4°C, and 
supernatants removed.  Pellets were resuspended in 2.3 M NaCl, 5% sarcosyl in 1X 
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PBS, centrifuges at 13,000 x g, washed three times in 50 mM Tris 150 mM NaCl, and 
were either stored dry or suspended in PBS at -80°C.  Presence of PK resistant prion 
rods were confirmed by western blot. 
 
Highly enriched prion rods were coupled to CM-5 sensor chips outside of the instrument 
after generating the reference flow cells within the instrument by activating with 
EDC/NHS and deactivating with ethanolamine three to five times. The chip was then 
removed from the instrument and the gold chip disassembled from the cassette.  The 
entire surface was activated with 100 µL of EDC/NHS for 12 minutes.  A pellet of rods 
was resuspended in 100 µL of 10 mM sodium acetate pH 5.4, sonicated at 37°C for 40 
seconds, and incubated on the gold chip at room temperature for one hour.  The chip 
was then briefly rinsed with 1X PBS, and remaining active groups were deactivated with 
ethanolamine for 7 minutes.  Prior to use in interaction analyses, a startup cycle of 50 
mM sodium hydroxide served to remove any nonspecifically bound prion rods from the 
surface. 
 
All SPR experiments involved recombinant PrP (rPrP) or prion rod enriched from 
infected brain as the ligand coated to a CM5 Series S sensor chip, and commercially-
available C1q (CompTech) as the analyte. C1q was buffer exchanged in Amicon filter 
devices into 1X Running Buffer (50 mM Tris HCl, 150 mM NaCl, pH 7.42). The rPrP-
coated chip was kindly provided by Dr. Hae-Eun Kang in the Telling lab. Briefly, flow 
cells were first activated with 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and 0.05 M N-hydroxysuccinimide (NHS) for seven minutes at 10 
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µL/min.  Amine coupling recombinant cervid or murine PrPC in 10 mM sodium acetate 
pH 5.5 was accomplished by flowing 20 µg/mL of ligand over the activated chip for 
seven minutes at 10 µL/min.  Excess activated groups were deactivated with 1 M 
ethanolamine HCl pH 8.5 for seven minutes at 10 µL/min.  Reference flow cells, built-in 
negative controls for this system, underwent rounds of activation and deactivation 
without the addition of protein ligand.    
 
Cell culture prion infection. N2a mouse neuroblastoma or rabbit kidney epithelial cells 
stably transfected with murine or elk Prnp-encoding plasmids were grown in RPMI 
medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. RML5 or E2 
infected brain homogenate was UV-sterilized prior to infecting cells. Infected brain 
homogenate was pre-incubated with PBS or C1q (5 µg/mL final) for at least 15 minutes 
prior to infecting cells. Cells were seeded at 100,000 cells per well in a 12 well plate and 
infected with 0.3% brain homogenates containing equal volume glycerol or C1q. Cells 
were grown at 37°C and 5% CO2 for 4 days. Wells were rinsed 2X in 1X PBS, and cells 
were detached from the plate using 5 mM EDTA in 1X PBS for 10 minutes. Cell pellets 
were resuspended in 100 µL PMCA buffer containing 1% Triton X-100 and lysed on ice 
for 30 minutes. Lysates were assessed for PrPRES using traditional PK digestion and 
western blotting techniques. 
 
Statistical analyses. All statistical analyses were performed using GraphPad Prism 
software. One- or two- way ANOVAs were run to compare genotype, sex, or the 
interaction between these two variables. P-values < 0.05 were considered significantly 
	
101 
different. In the terminal disease study, we observed one male outlier and subsequently 
removed this data point. Technical duplicates were averaged, and the mean value of 




C1q directly interacts with prion amyloid. Previous reports indicate C1q binds 
conformationally-modified recombinant PrP. Specifically, C1q interacts with PrP, but 
only when coated at a high density (Mitchell et al. 2007). We followed up this finding 
and showed that C1q preferentially bound coated PrP, whereas coated C1q minimally 
bound soluble PrP analyte (data not shown; previously published by others). We and 
Mitchell et al. (2007) conclude recombinant PrP on a Biacore sensor chip mimics 
aggregated PrP, and C1q only binds aggregated PrP. To test this hypothesis, we 
coated prion rods enriched from prion-infected hamster and elk brain and assayed for 
binding with C1q as an analyte (Figure 4.1). We report C1q binding hyper (HY) and 
drowsy (DY) transmissible mink encephalopathy (TME, Figure 4.1A), as well as elk 






Figure 4.1. C1q directly interacts with prion amyloid. Prion amyloid was enriched 
from infected brain homogenate as previously described (Safar et al. 1990) and 
manually coupled to a CM5 series S sensor chip. Surface plasmon resonance (SPR) 
analyses reveal that Complement component C1q binds prion amyloid. Concentrations 
of C1q for affinity analyses (bottom) included: 0, 1, 2, 10, 20, 100, and 200 nM.  
 
C1q paradoxically impedes CWD lymphotropism in transgenic mice. Previous reports 
highlight a crucial role for C1q in scrapie pathogenesis because C1q knockout mice 
resisted prion accumulation and clinical prion disease onset (Mabbott et al. 2001). 
However, the role C1q plays in CWD pathogenesis remained unknown. To test whether 
C1q impacts early events in CWD pathogenesis, ie lymphotropism, we inoculated 
Tg5037;C1q-/- mice with E2 prions and analyzed prion loads at various time points 
using PMCA. In contrast to previous reports on the role of C1q in scrapie, C1q knockout 
A 
B 

































0 50 100 150 200 250 300 350 400 450 500 550 600 650






















































































0 50 100 150 200 250 300 350 400 450 500 550 600 650











































































Kd:  10 nM 
B 


































Kd: 10 nM 
C1q (50 n ) C1q (50 nM) 
	
103 
mice paradoxically accumulated more prions at early time points than C1q sufficient 
Tg5037 mice. However, this experiment contains a number of confounding variables, 
including: C1q+/+ data was obtained from previous experiments and performed by 
different researchers (Michel et al. 2012); C1q-/- mice were generated on a 129 mixed 
background, whereas Tg5037 mice from Michel et al. (2012) were generated on an FVB 
background; and lastly, the researcher who collected the samples from this experiment 
mislabeled tubes which suggested the same mouse was taken at different time points.  
 
 
Figure 4.2. C1q paradoxically limits CWD splenic accumulation, yet promotes 
RML accumulation. C1q knockout (C1q-/-, solid line) mice received E2 CWD prions, 
were sacrificed at various time points, and prion loads were analyzed via PMCA (A). 
Comparing C1q-/- relative PMCA units (rpu) scores versus Tg5037 (dashed line) scores 
from Michel et al. (2012) reveal C1q knockout mice contained higher prion loads than 
Tg5037 mice by 30dpi. However, criticisms to this experiment include: no Tg5037 mice 
inoculated at the same time as C1q-/- mice; different mouse background strains; and 
mislabeling tubes suggesting the same mouse was taken at different time points.  
 
 
An attempt to control for caveats in Figure 4.2. As mentioned in Figure 4.2, early prion 
accumulation in spleen data were perplexing. We predicted CWD prions would, similarly 
to RML prions (Mabbott et al. 2001), utilize C1q to spread and propagate in spleen. 








































this trend. This could be due to: inoculating animals on different days; different mouse 
background strains; or human error. In attempt to control for the aforementioned 
caveats, we pre-treated E2 inoculum with 11 µg purified C1q and compared splenic 
prion load at 30dpi. If C1q indeed limits CWD accumulation, we would expect C1q pre-
treatment to reduce prion load in comparison to controls. Although not statistically 
significant, we observed the opposite trend. C1q pre-treatment slightly enhanced 
splenic PMCA scores (Figure 4.3B).  
 
 
Figure 4.3. C1q slightly enhances splenic CWD accumulation and early 
propagation in Tg5037;C1q+/+ mice. To compare the effect of C1q pre-treatment In 
mice of the same background strain that were inoculated on the same day, E2 inoculum 
was pre-treated with 11 µg C1q per mouse. Mice were sacrificed at 30dpi, and prion 
loads in spleen were analyzed via PMCA (A).  In contrast to Figure 4.2, C1q appeared 
to promote CWD accumulation, although this effect was not statistically significant. 
 
 
Cell culture systems may not parse out CWD vs RML reliance on C1q. In order to 
determine whether the discrepancy between Figure 4.2 and Mabbott et al. (2001) could 
be confirmed in cell culture systems, we infected rabbit kidney (RK) epithelial cells 











































































C1q exacerbates RML5 prion replication in N2a mouse neuroblastoma cells (Figure 
4.4C,D), we did not observe a difference in murine RK cells (data not shown). One 
experimental replicate showed C1q slightly reduced prion burden in elk PrPC-expressing 
RK cells. However, this finding was not repeatable (data not shown). Therefore, we 




Figure 4.4. In vitro prion infection assays +/- C1q pre-treatment. Rabbit kidney (RK) 
cells stably transfected with elk Prnp expression plasmid were infected with E2 +/- 5 
µg/mL C1q and analyzed for PK-resistant material via western blotting (A,B). Murine 
N2a cells were infected with RML5 +/- 5 µg/mL C1q and analyzed for PK-resistant 
material (C,D). While these non-representative images support in vivo findings on the 












































































C1q impedes the onset to clinical disease in a CWD transgenic model.  To determine 
whether C1q status dictates the time to clinical disease onset, we inoculated C1q 
knockout and hemizygous (C1q+/-) mice and monitored signs of clinical disease. We 
used historical Tg5037 controls (Michel et al. 2012) as discussed above. C1q knockout 
and hemizygous mice succumbed to prion disease at a significantly faster rate than 
historical Tg5037 controls (Figure 4.5). Further, C1q knockout mice appeared to contain 
increased prion amyloid deposition in cerebellum and cortex at terminal disease (Figure 







Figure 4.5. C1q delays the onset of terminal CWD in a transgenic mouse model. 
Time to clinical disease was assessed using a gene-dose transgenic mouse model and 
compared to historical controls. In alignment with early prion accumulation (Figure 4.2), 
C1q deficient mice succumbed to prion disease at a faster rate than C1q sufficient 
controls (A,B). Further, C1q-/- mice contained greater numbers of prion amyloid as seen 
via immunohistochemistry (C). However, the limitations to this study are similar to those 






Previous reports highlight a role for C1q in scrapie pathogenesis (Mabbott et al. 2001). 
However, whether C1q directly or indirectly impacts lymphotropism and/or 
neuropathological manifestations remains unclear. For example, perhaps C1q aids in 
prion opsonization and thus retention on CD21- and PrPC- expressing follicular dendritic 
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and B cells. Perhaps this retention increases the probability of contact between 
infectious prions and PrPC. However, as discussed in Chapter 3, prion opsonization 
could lead to increase phagocytosis and destruction by macrophages. The interplay 
between prions and the Complement system likely involves a delicate balance between 
both outcomes.  
 
We report C1q directly binds prion amyloid derived from CWD and TME infected elk and 
hamster brain, respectively. We hypothesize C1q promotes prion trafficking, retention, 
and propagation in the lymphoreticular system prior to neuroinvasion. Interestingly, we 
report C1q interacts with both lymphotropic (HY-TME and CWD) and non-lymphotropic 
(DY-TME) prion strains. Thus, we do not believe C1q dictates whether prion strains are 
lymphotropic. In fact, these data are quite perplexing because previous reports suggest 
C1q promotes lymphotropism. Perhaps C1q exerts its effects on prion propagation 
outside of the lymphoreticular system.  
 
The Complement system plays a larger role in the central nervous system than 
previously thought. Complement proteins C1q and C3 aid in synapse pruning during 
development (Stevens et al. 2007), and aberrant Complement-mediated synaptic 
pruning perhaps contributes to schizophrenia, autism, and early stages of 
neurodegeneration (Sekar et al. 2016). Further, Complement proteins are detected after 
brain injury (Bellander et al. 2000), and likely function to clear damaged tissue. Thus, 
Complement promotes normal physiology during development and in response to injury. 
However, the Complement system also leads to inflammation, and neuroinflammation is 
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thought to cause the ultimate death of pion-animals infected. Thus, ensuring the 
balance of normal physiology, yet preventing over-activation, may prove beneficial in 
the outcome of neurodegenerative diseases. 
 
Perhaps the enclosed findings are reproducible. If so, C1q poses opposite effects 
depending on prion strain. If this is indeed the case, perhaps C1q differentially binds 
scrapie prions. Future directions could involve enriching scrapie prion rods and 
assessing for interactions via SPR similarly to Figure 4.1. If C1q differentially binds 
scrapie prions, this could dictate downstream effects. Perhaps C1q binds scrapie prions 
with higher affinity than CWD prions. If so, C1q could more robustly activate the 
Complement cascade and thus promote neuroinflammation and ultimate death. This 
could explain why C1q knockout mice resist scrapie infection. However, future 
experiments are required to address this hypothesis. 
 
In summary, data presented in this chapter suggest C1q may impact CWD outcomes, 
yet confounding variables limit the interpretation of presented data. For example, in vitro 
experiments outlined in this chapter were not reproducible between researchers. 
Perhaps increasing technical replicates and/or titrating the concentration of C1q needed 
to observe a statistical difference are necessary. Further, in vivo experiments compared 
data generated from two researchers (myself and an undergraduate) to data generated 
from a former graduate student (Michel et al. 2012). We propose these findings need to 
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Prion diseases require host expression of the cellular prion protein, PrPC.  However, the 
precise function of PrPC remains elusive. Putative functions involving PrPC include: 
synaptic signaling in the hippocampus, cell adhesion, and T cell proliferation. PrPC 
signals via Src family kinase member, Fyn, and B cells activate via similar signaling 
molecules. PrPC expression is largely limited to cells of the immune and nervous 
systems, leading us to question whether PrPC provides a co-stimulatory signal to 
stimulate immune responses. We aimed to address three main questions: is PrPC 
regulated during an immune response? Are Prnp knockout mice immunocompromised? 
Does PrPC interact and signal with B cell co-receptor members? Upon stimulation with 
various immunological stimuli, cell-surface levels of PrPC reduce. However, whether this 
response promotes PrPC degradation, or perhaps intracellular signaling, remains 
unknown. We report no impairments of total B or T cell proportions in Prnp knockout 
(PrP KO) mice, although PrP KO mice exhibit impaired immune responses.  In vitro 
analyses reveal malfunctions in key signaling molecules downstream of B cell receptor 
engagement, as well as altered B cell receptor protein expression in PrPC deficient 
mice. PrP KO mice also reveal humoral impairments when vaccinated and challenged 
with Escherichia coli. Further, we report a direct interaction and co-localization between 
PrPC and B cell co-receptor member CD21. CD21 on B cells translocates to lipid rafts 
after engagement with complement-tagged antigens and reduces the activation 
	
113 
threshold. Altogether, data presented in this chapter reveal a pivotal role for PrPC in B 
cell activation signaling. Future directions include assessing the role of PrPC in the 
response to intracellular or gram positive pathogens, as well as testing whether PrPC 
aggregation could serve an immunological signal similarly to mitochondrial antiviral-




Mature, naïve B lymphocytes express surface immunoglobulin and various co-receptor 
proteins which coalesce in lipid rafts upon B cell receptor (BCR) engagement. When the 
BCR recognizes its specific antigen, subsequent events lead to B cell activation and 
antibody secretion, culminating in humoral immunity and host protection. However, prior 
to antibody production and secretion, several cell biological events must occur to 
activate a B cell. Upon antigen recognition, BCR and co-receptor proteins translocate 
into lipid rafts (Cherukuri et al. 2004; Sohn et al. 2008). Upon lipid raft coalescence, Src 
family tyrosine kinases phosphorylate Igα and Igβ cytoplasmic tails, leading to PLCγ2 
activation and calcium mobilization. These event precede antibody production and thus 
provide opportunities to monitor early events of B cell activation. 
 
The cellular prion protein, PrPC, is a 35 kD (human) glycoprotein permanently anchored 
to through GPI attachment to lipids which accumulate in cholesterol-rich membrane 
domains termed “lipid rafts.” PrPC consists of an unstructured N-terminal domain and 
contains heavy metal-binding octapeptide repeats. The C-terminal, structured domain 
becomes anchored to the plasma membrane after glycosylphosphatidylinositol (GPI) 
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addition. While previous research primarily focused on its requisite in prion diseases, 
the precise physiological function of PrPC remains elusive because Prnp-/- transgenic  
(PrP KO) mice appear to develop normally (Prusiner et al. 1993). However, work from 
the Strittmatter group reports synaptic signaling via the metabotropic glutamate receptor 
involves PrPC (Haas et al. 2016). Further, PrPC promotes neurite outgrowth via 
interactions with neural cell adhesion molecule (NCAM) and Fyn kinase (Santuccione et 
al. 2005). 
 
Most previous research on the role of PrPC in the immune system suggests a role in T 
cell proliferation and/or the immunological synapse between antigen presenting cells 
(APCs) and T cells. Specifically, Mabbott et al (1997) showed primary mouse 
lymphocyte proliferation in response to Con-A partially depended on PrPC because anti-
PrP antibodies abrogated proliferation. However, antibody treatment could potentially 
disrupt cell:cell interactions necessary for stimulation, and a brief literature search 
revealed rebuttals and debates regarding this study. Interestingly, however, PrP-/- 
dendritic cells (DCs) exhibited impaired PrP+/+ T cell stimulation, suggesting PrPC may 
exert its effect via APCs at the level of the immunological synapse (Ballerini et al. 2006).  
 
Several lines of evidence suggest PrPC may play a role in cell stress/immunological 
responses. For example, Shyu et al. (2002) reported Prnp mRNA upregulation in 
response to heat shock. Further, T cell mitogen PHA caused an upregulation in human 
T cells, and T cell proliferation in response to anti-CD3 was abrogated by anti-PrP 
antibody 8H4 (Li et al. 2001). Cashman et al. (1990) also reported cell-activation 
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increased surface levels of PrPC, and anti-PrP antibodies suppressed proliferation. 
Interestingly, Lotscher et al. (2003) also reported increased PrPC immunodetection in 
germinal centers and follicular dendritic cell networks after vesicular stomatitis viral 
infection. Collectively, these results suggest PrPC participates in immunological events 
leading to lymphocyte activation. 
 
While both B and T lymphocytes express PrPC to varying degrees, human CD8+ T cells 
express slightly higher levels than CD4+ positive T cells (Politopoulou et al. 2000 and 
Durig et al. 2000). CD8+ T cells help to provide protection against intracellular 
pathogens such as viruses, whereas CD4+ T cells aid in the protection against 
extracellular pathogens such as certain bacteria and helminths. Logic therefore serves 
to suggest PrPC plays a role in CD8+ cell signaling in response to an intracellular 
pathogen. However, Genoud et al. (2004) reported no deficiency in CD8+ T cell 
responses against cytotoxic lymphoctic choriomeningitis virus (LCMV) or vesicular 
stomatitis virus (VSV) in mice deficient in PrPC and its homolog Doppel. This was 
observed by LCMV-specific cytotoxic T lymphocyte numbers in blood, as well as 
antibody responses after vaccination. 
 
B cells can generate humoral (antibody) responses both dependent and independent of 
T cell help. Lipopolysaccharide (LPS) is an example of a T-independent antigen due to 
repeating structures capable of activating B cells even without cognate T cell help. 
Interestingly, PrP KO mice show increased susceptibility to LPS-induced septic shock 
(Liu et al. 2014). Furthermore, PrPC cross-linking induced calcium flux and ERK 
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phosphorylation in Jurkat T cells (Stuermer et al. 2004). ERK phosphorylation and 
calcium flux also occur in the process of B cell activation. Lastly, PrPC was found to co-
precipitate with Fyn kinase (Shi et al. 2013), another known member involved in B cell 
activation downstream of antigen recognition. Collectively, PrPC appears to augment T 
cell proliferation, yet T-dependent immunological responses to viral infection do not 
appear to depend on the expression PrPC (Genoud et al. 2004). Thus, the role of PrPC 
in an adaptive immune response remains unclear. Data provided in this chapter suggest 
PrPC promotes events leading to B cell activation and antibody production. 
 
 
Materials and Methods 
Mice.  All mice were bred and maintained at Lab Animal Resources, accredited by the 
Association for Assessment and Accreditation of Lab Animal Care Internationaland 
approved on January 14, 2016 by the Institutional Animal Care and Use Committee at 
Colorado State University (Protocol ID: 09-1580A). Prnp TALEN knockout mice on the 
C57/Bl6 background were kindly provided by Dr. Adriano Aguzzi (University Hospital - 
Zurich). Prnp knockout mice on the FVB background were kindly provided by Dr. Glenn 
Telling (Colorado State University). Blood and sera were collected from tail vein or 
cardiac punctures. Mice were vaccinated and boosted with weekly injections of 105 
heat-killed (HK) E. coli.  
 
Tissue collection and analysis. After euthanasia, cardiac punctures and spleens were 
collected. Blood was allowed to clot at room temperature for 10 minutes, centrifuged at 
1,000 x g for 10 minutes at 4°C, and serum was transferred to a fresh tube and frozen. 
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Spleens were processed to single-cell suspensions, and red blood cells were lysed as 
discussed below.  
 
In vitro activation. Splenocyte single-cell suspension cell density was determined by 
Bio-Rad cell counter, and 5x106 primary splenocytes were transferred to a separate 
tube and pelleted. Pellets were resuspended in 100 µL of RPMI media containing 10 
µg/mL anti-IgM (µ-specific, Invitrogen) or 10 µg/mL anti-CD40 (FGK45, Enzo Life 
Sciences) with cross-linking anti-rat secondary and incubated at 37°C for 5 minutes. 
Cells were pelleted and lysed in 90 µL ice-cold TNE buffer containing protease inhibitors 
(Roche, complete mini). Samples were run via western blot and probed for activated, 
phosphorylated Src (Y416, Cell Signaling 2101) via manufacturer guidelines. Blots were 
stripped and re-probed for GAPDH, and data was analyzed using ImageJ software and 
presented as percentage or fold change of GAPDH.  
 
ELISAs. E. coli-specific antibody responses were determined by ELISA. Heat-killed 
(HK) E. coli (4x106 CFUs) was coated in 100 µL solution carbonate/bicarbonate buffer 
(SIGMA) overnight at 4°C. Plates were washed multiple times and blocked in 300 µL 
5% nonfat dry milk (NFDM) in PBS containing 0.1% Tween 20 for one hour at room 
temperature. Sera (n=4 mice/genotype) was pooled prior to dilution. Trial experiments 
carried out two-fold sera dilutions ranging between 1:25 to 1:3200. Subsequent 
experiments carried out two-fold dilutions ranging between 1:25 to 1:400. Total IgG and 
IgG3 specific to HK E. coli were determined using HRP-conjugated secondary 
antibodies. Absorbance values from wells containing no sera were subtracted from all 
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wells. Thresholds per genotype were determined using pre-vaccination absorbance 
values. The average pre-vaccination absorbance value obtained from the lowest (1:25) 
sera dilution was added to the standard deviation multiplied by 3, and any post-
vaccination dilution above this value was considered a positive titer. Positive titers were 
imported into Graphpad Prism for statistical analysis. To compare total serum levels of 
IgG and IgG3, sera was diluted 1:25 to 1:200 and coated on a microtiter plate in 
carbonate/bicarbonate buffer and processed as discussed above.  
 
Surface plasmon resonance. All SPR experiments involved recombinant PrP (rPrP) as 
the ligand coated to a CM5 Series S sensor chip, and CD21 (commercially available or 
kindly provided by Dr. Johnny Hannan) were buffer exchanged in Amicon filter devices 
into 1X Running Buffer (50 mM Tris HCl, 150 mM NaCl, pH 7.42). The rPrP-coated chip 
was kindly provided by Dr. Hae-Eun Kang in the Telling lab. Briefly, flow cells were first 
activated with 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) and 0.05 M N-hydroxysuccinimide (NHS) for seven minutes at 10 µL/min.  Amine 
coupling recombinant cervid or murine PrPC in 10 mM sodium acetate pH 5.5 was 
accomplished by flowing 20 µg/mL of ligand over the activated chip for seven minutes at 
10 µL/min.  Excess activated groups were deactivated with 1 M ethanolamine HCl pH 
8.5 for seven minutes at 10 µL/min.  Reference flow cells, built-in negative controls for 
this system, underwent rounds of activation and deactivation without the addition of 




P3 cell culture. P3 myeloma cells were kindly provided by the Telling laboratory. Cells 
were grown in RPMI media containing 10% FBS and 1% penicillin/streptomycin. For 
immunocytochemistry, cells were grown on sterile glass coverslips placed in 3 mm 
culture dishes and were stained for CD21/35 (eFluor450), PrPC (Alexa Fluor 647), and 
lipid rafts (cholera toxin conjugated to Alexa Fluor 488). Some cells were treated with 
mouse complement containing HK E. coli to assess CD21/35 translocation into lipid 
rafts. However, we observed basal levels of CD21/35 in lipid rafts. Images were 
collected on an Olympus confocal microscope using 40X and 100X objective lenses.  
 
siRNA treatment. siRNA specific for Prnp transcripts were kindly provided by Heather 
Bender (Pulford et al. 2010). Splenocytes were treated with 40 nmole siRNA in 
OptiMEM for four hours. 
 
Direct Binding Assay. Recombinant human prion protein (rPrP) was kindly provided by 
the Hoover laboratory. Wells of a 96 well microtiter plate (Nunc) were coated with 1 µg 
rPrP or BSA in 100 µL carbonate/bicarbonate (SIGMA) buffer at 4°C overnight. Wells 
were washed and blocked in 300 µL 2% BSA in PBS. Wells were incubated for 24-48 
hours at 4°C with 1 µg CD21 kindly provided by Dr. Johnny Hannan. Samples were 
probed for CD21 using anti-CD21/35 (Santa Cruz) and anti-goat conjugated to 
horseradish peroxidase (HRP) secondary antibody. Wells were washed several times 
prior to incubation with 100 µL tetramethylbenzadine (TMB) at room temperature. 
Reactions were stopped using 0.5 M H2SO4, and O.D.450 was measured on a 
spectrophotometer.   
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Flow Cytometry (FACS). Fresh brain and spleens were harvested and processed to 
single-cell suspensions in 3 mL PBS. Briefly, tissues were passed through 40 µm mesh 
filters using sterile plungers and cold PBS washes. Cells were pelleted at 250 x g for 5 
minutes at 4°C, and the supernatant was discarded. Red blood cells (RBCs) were lysed 
in lysis buffer for 5 minutes, cells were pelleted as previous, and washed in FACS buffer 
(1X PBS, 1% FBS, and 1 mM EDTA). Primary splenocytes or brain suspensions were 
blocked in 7% mouse serum and 1:50 Fc block (BD Pharmagin) for 20-60 minutes on 
ice. Antibody solutions (1:100 final) were added to cells and incubated in the dark for 
one hour on ice. Cells were washed by adding 1 mL FACS buffer to existing antibody 
solution. Cells were pelleted, supernatant removed, and resuspended in 1 mL FACS 
buffer for a total of 3 washes. 792 µL cell suspension was added to 8 µL of Propidium 
Iodide (SIGMA) immediately prior to data acquisition in a Cyan flow cytometer.  Cells 
were analyzed 500-1500 events per second. Unstained samples were analyzed first in 
order to set parameters to achieve a well-defined peak in the first fluorescent decade. 
 
Escherichia coli culture. Laboratory strain E. coli was kindly provided by Pete Justice 
(Colorado State University). Single, well-isolated colonies were inoculated into Luria 
Broth (LB) and allowed to grow in a shaking water bath for 16-20 hours at 35 – 37°C. 
Culture titer was determined by plating various dilutions (100 µL) onto LB agar plates 
and counting colonies  >16 hrs after growth at 37°C or through obtaining O.D.600 value 
on spectrophotometer and calculated cell/mL using a Agilent Genomics calculator. For 
vaccinations and boosts, various concentrations of E. coli were heat-killed at 95°C for 5 
minutes at 800 rpm.  
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Calcium Signaling. Primary splenocyte single-cell suspensions were obtained as 
described above. Primary splenocytes (5x106) were loaded with 2 µM Fluo-4 at 37°C for 
30-45 minutes and washed three times in HBSS with 1 mg/mL BSA (HBSS/A). Baseline 
fluorescence (FITC) was obtained for one minute. Anti-IgM or anti-CD40 cross-linking 
antibodies (10X) were added to cells, pipetted to mix 3 times, and recorded for 5 
minutes.  
 
Lipid raft floatation. Naïve, non-vaccinated mice were inoculated with E. coli and their 
spleens harvested. Spleens were passed through 40 µm mesh filters, and 
approximately 20 million splenocytes were transferred to a fresh tube. Cells were lysed 
in ice cold TNE buffer (Michel et al. 2012) and passed through syringe and needle 22 
times while on ice. Lipid rafts were isolated using sucrose density gradients (9) and 
ultracentrifugation at 180,000 x g for 18 hours at 4°C. 
 
FACS analysis in Flow-Jo. Cellular debris was gated off the Y- axis of forward and side 
scatter plots. PI-positive (dead) cells were also gated off. Fluorochrome-positive gates 
were set by setting a threshold of 1% in the unstained population. In other words, 
stained cells were considered positive if their fluorescent intensity was greater than 99% 
of the unstained population. For calcium signaling experiments, calcium responders 
were determined by setting a gate above 1% of baseline fluorescence. Mean 
fluorescent intensity (MFI), as well as frequency of parent gate, values were imported 
into Excel and/or GraphPad Prism for analysis.  
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Statistical analyses. All statistical analyses were performed using GraphPad Prism 
software. P-values < 0.05 were considered significantly different. Technical duplicates 






In vitro stimulation causes reduction in cell-surface PrPC. To determine whether PrPC 
protein levels alter during the course of an immune response, we treated primary 
splenocytes with multiple immunological stimuli for various time points. FACS analysis 
revealed PrPC cell-surface levels were reduced when compared to untreated controls 
(Figure 5.1). However, these treatments may cause B cells to aggregate, so future 
directions should also include a B220+ B cell gate. In an attempt to confirm these 
findings, we treated PrP-expressing rabbit kidney cells (moPrP RK) with LPS and 
observed similar results, although with different magnitudes and kinetics. These data 
suggest PrPC internalization succeeds stimulation. However, whether PrPC destruction, 
or perhaps intracellular signaling, occur remains unknown. Therefore, we asked 






Figure 5.1. Cell-surface PrPC levels reduce after in vitro stimulation. To determine 
whether PrPC levels alter during the course of an immune response, primary 
splenocytes were treated with various immunological stimuli for various time points and 
analyzed for PrPC levels via FACS (n=4 FVB mice). Compared to untreated controls, 
splenocytes treated with various immunological stimuli (LPS or cross-linking antibodies 
against IgM or CD40) appear to contain less surface levels of PrPC (A). Although with 
differing kinetics and magnitudes, similar results were obtained after treating stably 
transfected rabbit kidney epithelial cells (moPrP RK cells) with LPS (B).  
 
Prnp deficient (PrP KO) mice develop normal splenic lymphocyte proportions and fare 
equal to wild type when naively challenged with E. coli.  Prior to testing B cell 
impairments, we tested whether PrP KO mice contain normal lymphocyte frequencies in 
spleen. FACS analysis revealed no impairments in total B220+, CD19+, or CD21/35+ B 
cells, nor their relative proportions (Figure 5.2A and data not shown). Previous reports 
indicate T-cell impairments in PrP KO mice, although this does not appear to be due to 
an impairment in total T cell numbers or proportions. Considering the putative role of 
PrPC in cell adhesion (Mange et al. 2002; Santuccione et al. 2005), we assessed 
whether PrP KO mice exhibited normal innate immune responses. Innate immune 
responses rely on white blood cell extravasation into infected tissue. Therefore, if PrPC 
regulates infiltration, we would have expected PrP KO mice to succumb to infection with 























































lower doses of live E. coli. However, 500,000 live E. coli cells, a modest dose, equally 
caused disease in wild type and knockout mice (Figure 5.2B,C). Inoculating mice with 
decreasing doses of E. coli may reveal subtle differences, although we do not believe 
this to be an appropriate use of live animals. Further, we observed a slight trend 
indicating PrP KO mice may have contained less bacterial burden than wild type (Figure 
5.2B). Importantly, C57/Bl6 mice resisted disease with a 20-fold higher doses of E. coli 
than FVB mice (Figure 5.2D), highlighting the importance of matching background 
strains. We therefore decided to test if fast-acting, cell-biological events in B cell 






Figure 5.2. Splenic lymphocyte proportions and naive, non-vaccinated survival 
against E. coli infection depends on mouse background, not Prnp status. To 
determine whether PrP KO mice contain normal levels of B and T cells in spleen, we 
analyzed B220+ B cells, CD3+ T cells, CD4+ T cells, and CD8+ T cells proportions via 
flow cytometry and did not observe any deficits (A, n=3 mice/genotype). PrP KO mice 
succumbed to infection without vaccination similarly to wild type mice after a single dose 
of live E. coli (B,C ANOVA p=0.0952). However, survival without vaccination depended 
on mouse background strain. C57/Bl6 mice survived after receiving 107 live bacteria, 
whereas FVB mice succumbed to infection with 5x105 live bacteria (n=1 mouse/dose, 
D), indicating a necessity to match background strains. 
 
PrPC promotes calcium signaling and Src family kinase (SFK) phosphorylation. B cell 
receptor engagement and CD40 ligation precede B cell activation and/or isotype 
switching. To monitor events downstream of BCR engagement or CD40 ligation, and 
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against IgM or CD40 and monitored calcium mobilization via FACS and SRC 
phosphorylation via western blotting. After cross-linking IgM, PrP KO mice exhibited 
significantly reduced calcium indicator dye fluorescence, indicative of less calcium 
mobilization (Figure 5.3A,B). Furthermore, SRC phosphorylation (Y416) in PrP KO mice 
did not statistically differ from untreated, whereas FVB wild type mice contained 
significantly higher SRC phosphorylation after IgM or CD40 cross-linking (Figure 5.3C). 
Lastly, we observed a significant difference in Lyn phosphorylation after challenging 
naïve mice with E. coli (Figure 5.2). These data highlight the necessity of PrPC in early 






Figure 5.3. PrPC augments early events in B cell activation. Calcium mobilization 
and Lyn and SRC phosphorylation precede antibody production and thus provide 
avenues to monitor early events in B cell activation. Spleens from mice in Figure 5.2B 
(n=6/genotype) were analyzed for phosphorylated Lyn via western blotting (A), and PrP 
KO mice contained a fewer proportion of phosphorylated Lyn kinase (p=0.0363 one-
tailed T test). Further, phosphorylation and activation of SRC kinase was impaired in 
PrP KO mice after in vitro activation (B). IgM (p=0.0242) or CD40 (p<0.0001) cross-
linking caused statistically significant increases in SRC phosphorylation (Y416) in FVB 
mice compared to untreated, whereas treated PrP KO splenocytes did not statistically 
differ from untreated. FVB and PrP KO primary splenocytes were loaded with calcium 
indicator dye Fluo-4, and fluorescence after IgM cross-linking was significantly higher in 
FVB mice compared to PrP KO (C p = 0.0059; data averaged over 5 minutes time 
course). Data in panels B-D were generated from n=2 mice/genotype, and experiments 
were repeated twice with 4 additional mice/genotype and showed similar results. 
 
PrPC bolsters humoral immunity and subsequent protection against extracellular 
bacteria. The above data suggests PrPC promotes signaling events in B cell activation, 
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leading us to question whether PrP KO mice exhibit impairments in humoral immunity. 
We vaccinated mice with 105 HK E. coli CFU, boosted twice, and compared total IgG 
and IgG3 responses in PrP KO and FVB wild type mice via ELISA. PrP KO mice 
contained significantly less IgG (all subtypes) and IgG3 specific to the coated vaccinate 
(Figure 5.4A,B). We calculated reciprocal IgG titers of >3200 and 400 for FVB and PrP 
KO mice, respectively. 
 
In a separate experiment, we coated serum on a microtiter plate and compared total 
levels of IgG and IgG3. We did not observe an impairment in total serum IgG or IgG3, 
suggesting these animals can indeed produce antibodies (Figure 5.4C,D). In fact, PrP 
KO mice contained significantly more serum IgG and IgG3 (discussed below). To 
ascertain whether vaccination protected PrP KO mice despite lower antibody responses 
to the vaccine, we inoculated mice with live E. coli (Figure 5.5). We chose a modest 
dose of 106 live bacteria, corresponding to a two-fold increase over dose known to 
cause sepsis in naïve, non-vaccinated animals (Figure 5.2). Twenty-five percent (one 
out of four) of PrP KO mice succumbed to infection despite vaccination, whereas all 
FVB mice were protected from infection (Figure 5.5). We predict vaccination would 
protect FVB mice from higher doses of bacteria, while PrP KO mice would succumb to 





Figure 5.4. PrPC bolsters humoral immunity after vaccination. To assess B cell 
function in relation to PrPC status, we vaccinated PrP KO and FVB mice and boosted 
weekly for a total of 3 injections. Serum was processed from tail vein blood collection 
prior to- and post- vaccination. Seroconversion and total serum IgG and IgG3 was 
assessed via ELISA. Vaccination induced seroconversion in both genotypes, although 
PrP KO mice contained significantly less total IgG (A, p=0.0119, T-test) and IgG3 (B, 
p=0.0003) against coated vaccinate. However, comparing total serum levels of IgG and 
IgG3 did not reveal an impairment in total immunoglobulin (C,D), and in fact showed 
that PrP KO mice contained significantly higher serum levels of IgG (p<0.0001) and 
























































































































   
Figure 5.5. Vaccination does not entirely protect PrP KO from infection with live 
E. coli. Vaccinated mice were challenged with 106 live E. coli  and monitored daily. 
Twenty-five percent (1/4) of PrP KO mice succumbed to infection, whereas vaccination 
entirely protected wild type FVB mice. Cultures of liver homogenate (B) showed only 
PrP KO liver contained septic infection. 
 
PrPC forms a complex with B cell co-receptor member, CD21. The B cell receptor and 
co-receptor include cell-surface IgM, CD19, CD21, and CD81. When complexed with 
C3d-tagged antigens, CD21, along with CD19, translocate to lipid rafts. Thus, we 
hypothesize PrPC stabilizes members of the B cell co-receptor in lipid rafts. If so, we 
predicted PrPC biochemically interacts with CD19, CD21, and/or CD81. We first tested 
CD21 and indeed observe an interaction. In a direct binding assay, coated recombinant 
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PrP bound CD21 when compared to a BSA negative control (Figure 5.6B). We also 
confirmed this finding with surface plasmon resonance (Figure 5.6A). Further, we 
observe the presence of PrPC, CD21, and cholera toxin conjugated to Alexa Fluor 488 
within lipid raft domains (Figure 5.6C). While we cannot conclude co-localization at this 
resolution, we provide evidence PrPC and CD21 form complexes both biochemically 
and within lipid rafts. Together, these findings suggest PrPC, a permanent lipid-raft 
resident, could bind translocated CD21 and perhaps augment signal transduction.  
 
 
Figure 5.6. PrPC forms a complex with B cell co-receptor member CD21. Data from 
previous chapters suggests CD21 impacts prion disease through direct interactions with 
prions. To determine whether CD21 also binds PrPC, we coated recombinant PrP on a 
CM5 sensor chip (A) or microtiter plate (B) and observed an interaction with 



































opsonized antigen induces translocation into cholesterol-rich signaling domains (lipid 
rafts). We observe overlapping signal between CD21 (eFluor450), PrPC (Alexa Fluor 
647), and cholera toxin B subunit (lipid raft marker, Alexa Fluor 488 courtesy of the 
Bamburg lab) in P3 myeloma cells (C). However, we cannot conclude co-localization at 
this resolution (40X). 
 
 
PrPC may promote CD21/35 translocation into lipid rafts. We initially hypothesized PrPC 
captures translocated co-receptors proteins and coordinates signaling events. To 
address this hypothesis, we isolated splenic lipid rafts from mice in Figure 5.2B and 
probed for CD21/35 (Figure 5.7). Although we detected FVB CD21/35 in lower-density 
lipid raft fractions than PrP KO mice, densitometric analysis did not reveal a deficit in 
total lipid raft CD21/35 between genotypes. This experimental paradigm presented a 
number of difficulties. For example, CD21/35 was invariably present in lower sucrose 
density fractions than lipid raft marker flotillin. Further, we never achieved concise 
separation between lipid raft and non- lipid raft fractions. Perhaps a more appropriate, 
future direction could include CD21/35 detection using microscopic techniques. For 
example, one could stain lipid rafts with fluorescently-labeled cholera toxin B subunits 
and analyze for CD21/35 presence (Figure 5.8). We attempted this experiment using P3 
myeloma cells treated with or without heat-killed E. coli, although we did not observe a 
difference between treated and untreated cells. Untreated lipid rafts contained 
substantial lipid-raft CD21/35, although perhaps other cell types and treatment 





Figure 5.7. PrPC may regulate CD21 translocation efficiency. Upon engagement 
with C3d/g-opsonized antigens, CD21 translocates into lipid rafts and cooperatively 
signals with B cell receptor and co-receptor members. To test whether PrPC promotes 
CD21 retention in lipid rafts, we separated lipid raft fractions (9) from non-lipid fractions 
via sucrose gradient ultracentrifugation from splenic lysates of FVB and PrP KO mice 
dosed with live E. coli (see Figure 5.2B). CD21/35 translocation into lipid rafts was 
determined by western blotting after probing for lipid raft marker flotillin, non-lipid raft 
membrane marker CD45R (B220), and CD21/35 (A; Top: fraction 1, Bottom: fraction 9). 
We observed CD21/35 in lower-density lipid raft fractions in FVB compared to PrP KO 
mice (B). However, we did not observe densitometric signaling differences in lipid raft or 
non-lipid raft fractions (C).   
 
 
PrPC regulates cell-surface CD19 levels. Considering PrPC and CD21 form complexes 
(Figure 5.6) and signal through similar SFKs (Chalupny et al. 1995 and Sempou et a. 
2016), we hypothesize PrPC serves a critical role in signaling with B cell co-receptor 
members CD21 and CD19. In PrP KO mice, we observed a slight, albeit non- 
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PrPKO 9 6-9 3-9 
PrPKO 9 4-9 4-9 
PrPKO 9 5-9 3-9 
FVB 8-9 6-9 2-9 
FVB 9 6-9 3-9 









us to question whether PrPC deficiency impacts CD19 levels. As discussed in Chapter 
3, B cell co-receptor members CD21 and CD19 form signaling complexes, and 
deficiency in one member impacts the other member’s cell-surface levels (Hasegawa et 
al. 2001 and Haas et al. 2002). To test whether PrPC deficiency impacts CD19 levels, 
we compared CD19 levels in wild type and PrP KO splenocytes via western blotting and 
FACS (Figure 5.8). Western blot densitometric analysis revealed higher CD19 levels in 
whole PrP KO splenocyte lysate (Figure 5.8A,B), and this was confirmed using FACS 
(Figure 5.8C). Naïve, PrP KO mice contain higher surface CD19 levels (Figure 5.8C), 
and siRNA treatment against Prnp transcripts in wild type splenocytes revealed the 





Figure 5.8. PrPC deficiency increases CD19 protein levels. To assess whether PrPC 
deficiency impacts B cell co-receptor member CD19, we analyzed protein levels via 
western blotting (A, B) and FACS (C, D). We observed statistically significant increase 
in CD19 normalized to GAPDH via western blot (A, B, p=0.0276). This finding was 
confirmed in naive primary splenocytes  (C, p=0.0331). To determine whether this effect 
was due to transgenesis, we treated wild type FVB primary splenocytes with siRNA 





Data presented in this chapter suggest PrPC augments B cell activation leading to 
humoral immunity against extracellular, gram-negative bacteria. While neural and 

















































































without overt phenotypes (Prusiner et al. 1993). However, research animals are kept in 
specific pathogen free environments, causing the potential to overlook 
immunodeficiency. While we do not observe an impairment in proportions of splenic 
lymphocytes (Figure 5.2), steps leading to B cell activation and antibody production 
appear to partially rely on PrPC (Figures 5.3 and 5.4). 
 
The B cell receptor and co-receptor include cell-surface IgM, Complement receptor 2 
(CD21), CD19, and CD81. Not surprisingly, genetic alterations leading to deficiency in 
any one of its members causes immunodeficiency. Data presented in this chapter 
suggest deficiency in PrPC also cause immunodeficiency. Putative prion disease 
therapeutics involve down-regulating PrPC. While these treatments would remove the 
prion substrate required for disease (Prusiner et al. 1993; White et al. 2008), we 
propose this treatment paradigm would also render a patient immunosuppressed. 
However, targeting siRNA treatments specifically to the brain (Pulford et al. 2016; 
Bender et al. 2016) would presumably circumvent this issue.  
 
Our FACS data suggesting PrPC becomes internalized after in vitro stimulation is in 
stark contrast with previous reports revealing an upregulation of PrPC after mitogen 
stimulus (Mabbott et al. 1997). Possible explanations could include: different cell types, 
mRNA versus protein, or different time courses. For example, surface PrPC may 
upregulate in T cells (Li et al. 2001) but not B cells (Figure 5.1). Further, mRNA changes 
may not always reflect changes in cell-surface protein levels (Shyu et al. 2002). Lastly, 
each study analyzed Prnp mRNA or protein products using different treatments and 
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time courses. Our data suggests PrPC may become internalized, but it’s unknown 
whether that’s to signal intracellularly or perhaps signals to stop the pro-inflammatory 
signal. A broader, longitudinal study with each stimulus and cell type is required to 
precisely determine Prnp regulation in response to immunological stimuli.  
 
B cell activation occurs both dependent and independent of T cell help. T-independent 
antigens usually contain highly repetitive structures such as lipopolysaccharide (LPS). 
T-dependent antigens only cause B cell activation when an activated T cell 
simultaneously recognizes its antigen presented in MHC II peptides on the cognate B 
cell. CD40 ligation between a B cell and its corresponding helper T cell promotes B cell 
activation and immunoglobulin isotype switching. Treatments with IgM or CD40 cross-
linking antibodies mimic T- independent or dependent activation, respectively, and lead 
to different B cell phenotypes (Wortis et al. 1995). Interestingly, PrPC appears to 
regulate B cell activation in response to T-dependent or -independent antigens because 
we observed impaired SRC phosphorylation in PrP KO splenocytes after cross-linking 
IgM or CD40 (Figure 5.3). While heat-killed E. coli contains both T- dependent and 
independent antigens, future studies could include vaccinating mice with purified LPS or 
protein antigens to parse out differences, if any.  
 
Previous reports indicate a role of PrPC in T cell proliferation in response to mitogenic 
stimuli (Mabbott et al. 1997), and cross-linking PrPC in Jurkat T cells led to increased 
intracellular calcium mobilization and ERK phosphorylation (Stuermer et al. 2004). The 
data presented in this chapter suggest PrPC may also regulate calcium signaling and 
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SRC phosphorylation in B cells (Figure 5.3). Taken together, these data highlight a 
crucial role for PrPC in lymphocyte signaling cascades. However, future studies are 
required to ascertain the precise roles of PrPC on B and T cells, as well as the 
interactions between the two.  
 
Several studies suggest PrPC serves as an adhesion molecule (reviewed in Petit et al. 
2013). For example, PrPC overexpression caused N2a cells to aggregate in a calcium-
independent manner (Mange et al. 2002). This datum suggests PrPC may promote 
intercellular adhesion. Future studies could include testing whether PrPC aids 
immunological synapse formation between antigen presenting cells and T cells. 
Whether PrPC promotes cell:cell contact, brings together signaling molecules to raft 
domains, or perhaps both, remains unclear. Future directions could include testing 
whether PrP KO mice sufficiently form immunological synapses between T cells and 
APCs.  
 
When engaged with opsonized antigens, CD21 and CD19 complex translocates to lipid 
rafts and reduces the signaling threshold to activate a B cell. CD19, a transmembrane 
protein, becomes phosphorylated and recruits Src family kinases to the membrane. 
Studies of CD19 transgenic mice reveal CD19 roles in B cell survival and activation. 
CD19 deficient mice reveal deficits in BCR signaling (Depoil et al. 2008) and elicit 
reduced IgG responses to vaccination (Gardby et al. 2001). Interestingly, CD19 over-
expressing transgenic (hCD19TG) mice contain higher immunoglobulin levels in an 
isotype-dependent manner. Specifically, hCD19TG mice contain higher IgG2b levels, 
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yet lower IgG3 titers (Engel et al. 1995). We observe increased CD19 (Figure 5.8) and 
total serum IgG3 (Figure 5.4) in PrPC deficient mice. CD19 augments B cell activation 
and antibody production, yet we report humoral impairments after vaccination in mice 
which overexpress CD19 yet lack PrPC. Thus, CD19 overexpression in PrP KO mice 
does not compensate for the antibody impairments to vaccination seen in PrP KO mice. 
Perhaps CD19 cannot effectively recruit Src-family kinases Fyn and Lyn (Chalupny et 
al. 1995) or form lipid raft microclusters (Sohn et al. 2008) in the absence of PrPC. 
 
An alternative explanation to findings in this chapter could be PrP KO mice contain 
overall higher serum IgG levels due to mounting an antibody response against a 
concurrent infection. However, both strains of mice were age-matched, co-housed, and 
inoculated on the same days. We do not believe PrP KO mice were exposed to other 
pathogens, although we cannot entirely rule out this possibility.  
 
Another possible explanation is that PrP KO mice effectively generate certain classes of 
immunoglobulin, but not others. For example, PrPC may regulate certain isotype 
switching. CD40 ligation stimulates B cells to isotype switch, and we observe reduced 
Src phosphorylation in PrP KO mice downstream of CD40 cross-linking (Figure 5.3). 
Future experiments could involve longitudinal studies to determine precise isotype 
switching impairments, as well as T cell dependent and independent antigens. For 
example, crude heat-killed E. coli contains both T-independent antigens (LPS), as well 
as T-dependent antigens. Future experiments could test humoral responses to purified 
antigens. However, our findings suggest PrPC plays a role in both responses because 
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IgM and CD40 cross-linking both at least partially relied on PrPC. IgM cross-linking 
serves as a model for T-independent activation, whereas CD40 ligation generally 
involves interactions between T cells and antigen presenting cells.  
 
The enclosed experiments used PrP KO Zurich-1 mice (Bueler et al. 1992) back-
crossed on the FVB background (Prusiner et al. 1993). While these mice have proven 
useful in ascertaining the role of PrPC in prion disease pathogenesis, Dr. Adriano Aguzzi 
argues effects observed in these mice may arise from transgenesis and back-crossing 
artifacts. Therefore, he generated TALEN PrP KO mice on the C57/Bl6 background 
which specifically targets small sequences in Prnp without off-target effects (Nuvolone 
et al. 2016). Therefore, we propose confirming the enclosed findings using the TALEN 
KO mice. Preliminary findings show the same trend with in vitro findings, although not 
statistically significant. Hurdles experienced thus far include large sample standard 
deviations, although perhaps optimizations in different mouse background strains are 
required.  
 
Hou and colleagues (2001) published a seminal finding regarding mitochondrial 
antiviral-signaling protein (MAVS) aggregation in response to viral infection. Yuan and 
Hochschild (2017) reported the bacterial transcription terminator Rho no longer 
efficiently terminates transcription in its aggregated state. Further, yeast prions form in 
response to various environmental stressors. Thus, protein aggregation (“prion 
formation”) can serve normal, physiological functions in response to insults. We propose 
PrPC, particularly considering its propensity to aggregate and misfold, may also 
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aggregate in response to immunological stressors. Interestingly, PrPC is present in 
healthy mice mitochondria (Faris et al. 2017). In light of data presented in this chapter, 
among others, we hypothesize immunological stimuli cause PrPC to internalize (Figure 
5.1) and aggregate, and this response may involve mitochondria. If this hypothesis is 
indeed true, perhaps prion diseases arose from aberrant, non-resolvable misfolding in 
response to stressors. We began to optimize testing this hypothesis using semi-
denaturing assays such as SDD-AGE, although PrPC abundance in whole spleen 
limited detection capability. Further, PrPC in normal (non-infected) brain ran in an 
aggregated state. Future experiments could involve testing varying concentrations of 
detergent and/or electrophoresis parameters.  
 
In summary, we conclude PrPC is the newest discovered member of the B cell co-
receptor. We provide three lines of evidence: 1) PrPC signals through similar SFKs as 
the B cell receptor and co-receptor (Mouillet-Richard et al. 2000; Shi et al. 2013; 
Pleiman et al. 1994; Chalupny et al. 1995); 2) SFK phosphorylation, calcium signaling, 
and humoral responses after at least partially rely on the presence of PrPC (Figures 5.3 
and 5.4); and 3) Purified PrPC directly interacts with co-receptor member CD21 (Figure 
5.6). Future directions could include testing direct interactions between PrPC and other 
B cell co-receptor members. Experiments to address this include co-
immunoprecipitation, surface plasmon resonance, and/or direct binding assays. We 
hypothesize PrPC, a permanent lipid-raft resident, coordinates signaling partners to aid 
B cell activation. Intriguingly, Susan Pierce’s group predicted a GPI-anchored member’s 
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CHAPTER 6 – GENERATION OF PRION-SPECIFIC NANOBODIES: BIOCHEMICAL 




Four peptides, two heavy and two light chains, comprise canonical immunoglobulin G. 
However, camelids also generate heavy-chain only antibodies. Previous researchers 
generated molecular biology protocols to clone the variable domain of these heavy-
chain antibodies which maintain full binding capacity and usually exhibit binding 
affinities within the low nanomolar range. Nanobodies preferentially bind three-
dimensional epitopes, such as enzymatic clefts and perhaps the prions. Here we report 
immune library construction derived from an alpaca vaccinated with recombinant white-
tailed deer prion protein. We identified a minimum of two clones which may 
preferentially bind prion-infected brain. Future directions include screening additional 
potentially reactive clones, as well as testing whether these nanobodies prevent or 
delay prion infection in vitro and in vivo. Further, we propose comparing binding 
capacities between different prion strains, if any. Collectively, data presented in this 
chapter outline a molecular biological approach to generate prion-specific antibody tools 




Canonical G immunoglobulins are heterodimeric tetramers with both light and heavy 
chains (see Figure 6.1). Camelidae species, such as camels, llamas, and alpacas, 
generate these conventional antibodies, but also produce antibodies devoid of light 
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chains. These IgG2 or IgG3 heavy-chain antibodies (HCAbs) lack the constant heavy 
chain region CH1 (Hamers-Casterman et al. 1993) which anchors the light chain to the 
heavy chain (Padlan 1994). Thus, heavy-chain antibodies are much smaller than 
conventional antibodies yet maintain full binding capacity. Ghahroudi et al. (1997) 
reported a molecular biology technique which involved cloning the variable domain of 
the camel HCAb variable domain (VHH), later termed “nanobody.”  Nanobody affinity 
analyses reveal dissociation constants (Kd) within the nanomolar range (Pain et al. 
2015; Schoonaert et al. 2017), which are comparable to mouse monoclonal antibodies 
(van der Linden et al. 1999).  
 
Potential nanobody applications seem boundless. Nanobody sequences share high 
homology with human variable domains, and are thus considered weakly immunogenic 
(Klarenbeek et al. 2015). Therefore, nanobodies may offer treatment opportunities 
which are limited in murine antibody treatments. Murine antibodies often prove 
successful after the first administration, but repeated administrations fail due to an 
immune response against the murine antibodies. Considering nanobodies share such 
high homology with human variable domains, it seems possible that repeated 





Figure 6.1. Cartoon diagram of camelid antibodies discussed in this chapter.  
Species from the Camelidae family generate conventional antibodies with both heavy 
(red) and light (blue) chains (left), as well as antibodies devoid of light chains (middle). 
Molecular biology techniques provide the ability to clone the variable heavy chain 
domain (VHH, right), which maintains high affinity interactions. 
 
Nanobodies preferentially bind structural (3D) epitopes. Amyloidogenesis involves 
protein conformational changes which convert normally soluble proteins into an 
insoluble, aggregation-prone state. Considering nanobodies preferentially bind 
structural epitopes, perhaps they could provide mechanistic or therapeutic avenues to 
discriminate between native and misfolded forms and perhaps treat protein misfolding 
disorders. For example, Domanska et al. (2011) reported a nanobody clone which 
prevents ß2-microglobulin fibrillation in vitro. Revealing the epitope binding domain 
could not only provide structural information on exposed epitopes, but may also provide 
a therapeutic opportunity to prevent amyloidogenesis in vivo. For example, Guilliams et 
al. (2013) reported a nanobody-binding domain as soluble after fibrillation. These 




















findings may help identify exposed vs buried epitopes in amyloid and thus provide 
information regarding amyloid conformations and therapeutic targets. If these findings 
are translatable to other amyloid-prone proteins, such as the prion protein, perhaps 
nanobodies could not only provide mechanistic information on prion formation, but may 
also provide a therapeutic opportunity to combat disease.  
 
Various in vivo data suggests nanobodies provide various disease therapeutic 
opportunities. Nanobody administration reduced viral replication and morbidity and 
mortality rates in a H5N1 influenza mouse model (Ibanez et al. 2011). Further, 
antibodies with basic isoelectric points (e.g. 9.4) can spontaneously cross the blood 
brain barrier (BBB, Li et al. 2012). While the large nature of conventional antibodies 
greatly impedes this process, nanobodies offer potential therapies for various 
neurological diseases and disorders. Therapies targeting central nervous system 
diseases, such as Alzheimer’s Disease, Parkinson’s Disease, prion diseases, etc, are 
limited due the difficulty in crossing the BBB. Further, the aforementioned diseases all 
contain a protein misfolding component. If nanobodies can spontaneously cross the 
BBB and recognize certain protein confomers, they may offer the cure-all for multiple 
CNS diseases.  
 
Pardon et al. (2014) outlined a molecular biology protocol to clone the HCAb variable 
domain which generates 12-15 kD product termed nanobodies (see Figure 6.2). These 
nanobodies preferentially bind three-dimensional epitopes such as enzyme catalytic 
clefts (Li et al. 2012a), are weakly immunogenic due to high homology between human 
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and camelid variable domain framework region (Klarenbeek et al. 2015), and their small 
size provides therapeutic potentials.  
 
Briefly, Pardon et al. (2014) outlined buffy coat RNA islation and immune library 
construction via phage display (Figure 6.2). Camelid species generate robust HCAb 
responses after vaccination and several boosts. After the 6th or 7th boost, isolated buffy 
coat RNA contains HCAb mRNA which can be used to generate an immune library. 
Cloning VHH specific sequences into a phage display vector, followed by phage 
packaging and panning, can lead to identifying specific clones which produce HCAb 
against your targeted immunogen. After inducing protein expression and purifying 
putative clones, one can test specificity. Further, comparing sequence homology 




Figure 6.2. Nanobody library construction experimental design. Camelid species, 
such as alpacas, generate a robust antibody response after vaccination with 
recombinant white-tailed deer PrP (rWTD) and multiple boosts. Lymphocyte-
concentrated blood fraction, termed buffy coat, contains antibody-producing B cells. 
RNA extracted from buffy coats contain PrP-specific nanobody transcripts. These 
sequences are reverse transcribed into cDNA, and VHH sequences are PCR-amplified 
to contain restriction enzyme sites. Using these restriction sites, nanobody-specific 
sequences are ligated into a phage display vector. This library is packaged into M13 
helper phage, and antigen binders are selected after multiple pans of phage display. 
Putative clones are sequenced, purified, and screened for specificity.     
 
Data presented in this chapter aimed to generate an immune library and clone 
nanobodies from an alpaca vaccinated with recombinant PrP (rPrP). While we 
encountered difficulties in immune library efficiency, we identified12 clones which 
specifically recognize PrP. We screened 4 of the 12 potential candidate clones, and 
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present data which suggests two clones generate nanobodies which preferentially 
recognize infectious forms of PrP.  
 
 
Materials and Methods 
Alpacas. Alpacas were maintained by Dr. Dick Bowen at Colorado State University and 
accredited by the Association for Assessment and Accreditation of Lab Animal Care 
International and approved on January 14, 2016 by the Institutional Animal Care and 
Use Committee at Colorado State University (Protocol ID: 09-1580A). Alpacas were 
vaccinated and bled from the jugular vein by Dr. Valerie Johnson or Dr. Danielle Adney. 
A current graduate student in the Zabel laboratory, Savannah Rocha, extracted buffy 
coat RNA, reverse-transcribed RNA into cDNA, and amplified VHH-specific cDNA 
molecules via PCR. In a nested PCR reaction, Pst1 and Eco91I restriction sites were 
added to the ends of amplified VHH sequences (see her future dissertation for details). 
The following methods were perfomed as outlined in Pardon et al. (2014).  
 
Seroconversion test via western blotting. To confirm a humoral response against the 
recombinant PrP vaccine, serum diluted 1:500 was probed against purified immunogen 
ran via western blotting. A polyclonal anti-camel antibody conjugated to HRP was used 
as the secondary antibody, and images were obtained after addition of 
chemiilluminescent substrate. Savannah Rocha tested serum via ELISA under my 
supervision, and obtained a 120,000 reciprocal titer (data not shown). However, serum 
was highly reactive to Prnp-/- brain homogenate via western blotting (data not shown), 
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and we did not obtain observable differences between knockout and PrPC-expressing 
brain homogenates via western blotting. 
 
Immune library cloning. VHH-specific cDNA sequences with PstI/Eco91I recognition 
sequences were ligated into phage display vector pMESy4. pMESy4 (10 µg purified 
plasmid) was digested in a 250 µL reaction containing PstI, Eco91I, and XbaI. At the 
same time, amplified PCR product (3 µg) was digested in a 100 µL reaction with PstI 
and Eco91I. Test ligations with 30 ng of digested product ligated into 100 ng digested 
vector (3:1 molar ratio) and electroporated in TG1 cells yielded lower efficiency than 
outlined in Pardon et al. (2014). To determine ligation and amplification efficiency, 
individual colonies were suspended in 50 µL DEPC water and screened for nanobody 
insert via PCR using MP57 (5’ TTATGCTTCCGGCTCGTATG 3’) and GIII (5’ 
CCACAGACAGCCCTCATAG 3’) primers. The majority did not contain the proper sized 
insert. Therefore, we performed a large-scale ligation with a 6:1 molar ratio of 
product:vector in order to maximize the number of transformants in the immune library. 
The ligation products were purified with a PCR purification kit and electroporated into 
TG1 cells. Recovered cells (100 µL of 8 mL total) were diluted to determine effective 
library size, and the remaining cells were grown on large square (245 mm x 245 x 25 
mm) bioassay dishes dishes containing LB agar with 100 µg/mL ampicillin and 2% 
glucose. The immune library was recovered by adding 4 mL LB onto the plate and 
combining all colonies using a scraper. OD600 values were obtained, and glycerol (20% 




Phage packaging, amplification, and titering. Six OD600 units of immune library glycerol 
stocks were grown at 37°C and 200 rpm to logarithmic phase in 60 mL 2X TY media 
containing 100 µg/mL ampicillin and 2% glucose. Culture was divided up into 10 mL 
aliquots and superinfected with ~10X phage:TG1 ratio, equating to 4x1010 plaque 
forming units (pfus) of M13 helper phage. Cells were incubated without shaking for 30 
minutes at 37°C and centrifuged at 3,000 x g for 10 minutes. Pellets were resuspended 
in 50 mL 2X TY containing 100 µg/mL ampicillin and 25 µg/mL kanamycin and grown 
overnight at 37°C. Cultures were centrifuged at 3,000 x g for 20 minutes, and phage-
containing supernatant (40 mL) was transferred to a fresh tube. Phage was precipitated 
by adding 10 mL 20% PEG6000 and 2.5M NaCl, inverting five times, and sitting on ice 
for 30 minutes. Precipitated phage particles were pelleted at 3,200 x g for 10 minutes at 
4°C. Supernant was discarded in bleach, and any remaining liquid on the pellet was 
removed by gently inverting the tubes over kim-wipes. Phage particles were 
resuspended in 1 mL ice-cold PBS and centrifuged at 20,000 x g at 4°C for 1 minute in 
a microcentrifuge (Telling lab) to pellet remaining bacteria. Supernatant was transferred 
to a fresh tube. Phage was re-precipitated by adding 250 µL PEG/NaCl buffer (above) 
to the supernatant, and tubes were inverted 10 times and sat on ice for 10 minutes. 
Phage was pelleted at 20,000 x g at 4°C for 15 minutes, and the supernatant was 
removed. Phage was resuspended in 1X PBS and centrifuged for 1 minute to remove 
any remaining bacterial cells. Supernatant containing amplified phage was titered in 
logarithmic-phase TG1 cells. Briefly, 90 µL logarithmic-phage TG1 cells were infected 
with 10 µL phage dilution, and 5 µL was plated on LB agar plates containing 100 µg/mL 
ampicillin and 2% glucose. 
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Phage panning to identify target-binders. To enrich phage particles which specifically 
bind PrP, we coated 1 µg recombinant white tailed deer PrP or Superblock on a 
microtiter plate (Nunc) in carbonate/bicarbonate buffer (SIGMA) at 4°C for 24+ hours 
and was washed with PBST (0.05% Tween 20). Note that pilot experiments included 
nonfat dry milk instead of Superblock as a negative control, but Superblock was 
determined to bind less phage particles nonspecifically. Further, we also employed 
various conformational tests, such as capturing PrP after coating anti-PrP (BAR224) 
antibody to the plate or first coating poly D-lysine. However, the final clones identified 
were screened against PrP coated to the microtiter plate. PrP-coated microtiter plates 
were blocked in 250 µL 2% NFDM (“blocking buffer”). Per selection or control well,1011 
pre-packaged phage was pre-incubated with 10 µL blocking buffer and 100 µL PBS and 
was mixed by head-over-head rotation for 30 minutes. 100 µL of phage was incubated 
on PrP-coated wells for 2 hours at 700 rpm. Phage was removed by pipetting, and wells 
were washed 15 times with 250 µL PBST. Phage was trypsinized and transferred to 
microcentrifuge tubes containing PMSF to halt trypsin activity. Phage was titered as 
described above. Glycerol stocks were generated by infecting exponential-phase TG1 
cells with 50 µL trypsinized phage and grown overnight in LB containing 100 µg/mL 
ampicillin and 2% glucose (“sublibrary”). Glycerol stocks were stored at -80°C. 
Subsequent rounds of panning further enriched the phage display library to select for 
clones which specifically recognize PrP. Glycerol stocks (500 µL) were grown to 




Immune library master plate generation and analysis. Various dilutions of sublibrary 
cultures were plated on selective agar medium and grown for ~16 hours at 37°C.  
Individual colonies (96) were inoculated into each well of a 96-well round-bottom culture 
plate containing 100 µL 2X TY medium containing 100 µg/mL ampicillin, 2% glucose, 
and 10% glycerol. One well was inoculated with a Superblock-panned control, and one 
well was not inoculated with a colony. This master plate was grown overnight at 37°C 
without shaking. To obtain periplasmic extracts to screen via ELISA, 10 µL of the master 
plate was inoculated into medium, sealed with a gas-permeable screen, and grown for 3 
hours at 37°C with shaking. IPTG addition (100 µL of 10 mM solution) induced 
nanobody expression, and the plate was shook at 37°C and 200 rpm for 4 hours. Cells 
were pelleted at 3,200 x g for 10 minutes, supernantants were discarded, and cells were 
lysed by freezing dry pellets at -20°C for 30 minutes. The plate was thawed at room 
temperature for 15 minutes, and pellets were resuspended in 100 µL PBS. Periplasmic 
extract (1:5) reactivity was screened via ELISA.  
 
Nanobody specificity analysis. Soluble nanobodies were expressed in E. coli strain 
BL21. First, small amounts of A2, A9, B10, and B11 (identified by highest periplasmic 
extract reactivity) from master plate wells were scraped into selective LB medium and 
grown overnight. Plasmid was extracted using manufacturer’s instructions. Plasmid was 
transformed into BL21 cells, and individual colonies were grown overnight in 10 mL LB 
containing 100 µg/mL ampicillin, 2% glucose and 1 mM MgCl2. The next day, 3 mL of 
culture was inoculated into 330 mL TB media containing 100 µg/mL ampicillin, 0.1% 
glucose, and 1 mM MgCl2 until O.D.600= 0.7. Nanobody expression was induced by 
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addition of 1 mM IPTG. After induction, cultures were centrifuged for 15 minutes at 
9,000 x g. Pellets were resuspended in 15 mL ice-cold TES, incubated for 1 hr, and 30 
mL TES/4 was added and incubated for 45 minutes. Periplasmic extract was collected 
after pelleting cellular debris for 30 minutes at 10,000 x g and 4°C. The His-tagged 
nanobodies were purified on an IMAC column per the manufacturer’s instructions. We 
biotinylated the purified nanobodies, and screened for specificity via western blotting 
and ELISA using streptavidin conjugated to HRP for nanobody detection.  
 
Nanobody sequence analysis. Clones A2, A9, A10, A12, B7, B8, B10, B11, C2, and 
E10 from master plate were grown up, and plasmid was purified according to the 
manufacturer’s instructions. Plasmid and MP57 and GIII primers were sent to and 
sequenced by QuintaraBio. All sequence analysis, including alignments and protein 
translation, was performed using Serial Cloner software.  Sequences from Schoonaert 
et al. (2017) were used to identify complementarity determining region number 3 
(CDR3) sequences in the master plate nanobody sequences, and protein alignments 




Robust alpaca seroconversion after vaccination and boosts.  We tested 
immunoreactivity against purified immunogen via western blot (Figure 6.3). A serum 
dilution of 1:500 used as the primary antibody source was so reactive, one could see 
the chemiluminescent reaction develop with the naked eye. Future experiments should 
use much more dilute serum. Indeed, another researcher determined the serum to 
	
159 




Figure 6.3. Alpaca serum contains highly-reactive antibodies after the 6th boost. 
Western blotting analysis reveal robust seroconverison after vaccination and boosts. 
Sera (1:500 dilution) detected purified recombinant PrP from various species (WTD: 
white-tailed deer). These particular western blots were so saturated, one could see the 
chemiluminescent reaction by the naked eye directly after substrate addition.  
 
 
Cloning scheme for phage display. After determining the alpaca did indeed generate a 
robust antibody response, a fellow researcher extracted buffy-coat RNA, reverse 
transcribed into cDNA, and PCR-amplified VHH sequences to contain restriction 
enzyme sites (see Figure 6.2). These sequences were ligated into the pMESy4 phage 
display vector (Figure 6.4A). Briefly, the vector was cut with PstI, Eco91I, and XbaI, and 













































































































































































































































Figure 6.4. Phage display vector pMESy4 vector map and analysis. Nanobody-
encoding VHH sequences are ligated into phage display vector map pMESy4 (left). We 
electroporated purified pMESy4 into TG1 cells, grew up, and purified plasmid. Agarose 
gel electrophoresis showed plasmid integrity and restriction enzyme site integrity (right).   
 
 
Low percentage of nanobody-specific clones. PCR-amplified VHH sequences were 
ligated into pMESy4 at a 3:1 insert:vector molar ratio. Initial test screens reveal a small 
proportion of clones contained intact nanobody insert using MP57 and GIII primers 
(Figure 6.5). We hypothesize a number of nanobody sequences contained restriction-
enzyme sites within the ligated VHH sequence. Thus, a digested, shorter sequence 
would be ligated into the vector. Indeed, it appears many clones contained shorter 
















Figure 6.5. Initial screens show low percentage of clones containing true 
nanobody inserts. We performed a small-scale ligation and tested individual clones for 
nanobody-specific sequences. Digested insert was ligated into digested vector (3:1 
insert:vector molar ratio) and electroporated into TG1 cells and plated on LB/Ampicillin 
agar plates (left). Individual colonies were screened for nanobody insert using MP57 
and GIII primers (right). Each lane represents one clone, and bands highlighted with a 
blue box represent clones with true nanobody insert (~700bp).    
 
Large-scale immune library construction. Pardon et al. (2014) described an efficient 
library containing 107 positive clones. Considering the small-scale test ligation showed 
less than 75% of clones contained true nanobody (Figure 6.5), we increased the molar 
concentration of insert:vector to 6:1 instead of 3:1. However, despite this change, we 
generated a less-than-ideal library, which we calculated to be 1.14x105 CFU/mL. We 
generated 3 mL of this library (or 342,000 total clones), equating to roughly 20-times 
less than the ideal library outlined in Pardon et al. (2014). However, we obtained a high 
phage titer (4.0x1012 CFU/mL, Figure 6.6C) after growing up and infecting the immune 




















Figure 6.6. Large-scale library production and phage packaging. Due to the ligation 
test run inefficiency (Figure 6.5), we increased the insert:vector raio to 6:1 and 
generated a library of 1.14x105 CFU/mL (A,B). We grew 6 OD600 units of immune library 
(A) to logarithmic phase and super-infected with M13 helper phage. Amplified and 
precipitated phage was titered in naïve TG1 cells (C) and generated a high titer of 
4x1012 CFU/mL. Note this titering protocol outlined in Pardon et al. (2014) differs from 
traditional phage titering with plaque forming unit (pfu) readout. Therefore, titers are 
reported as CFU instead of PFU.   
 
 
Phage-panning round 1. To enrich PrP-recognizing phage particles, we panned library 
phage particles (Figure 6.6) on a microtiter plate coated with recombinant WTD PrP or 
Superblock negative control. Pilot experiments also employed use of poly-D-lysine, 
capture antibody BAR224, or nonfat dry milk, although we observed a great deal of 













alone. The first panning round did not show a difference between phage panned on PrP 
or negative controls (Figure 6.7). Therefore, we employed a second round of panning 
from phage particles grown up and precipitated from the first round (Figure 6.8). Phage 
panned on Superblock in round 1 did indeed positively pan on Superblock in round 2 
(Figure 6.8), suggesting some immune library clones cross-react with the negative 
control Superblock. However, we obtained undefined enrichment between phage 
particles panned on PrP in round 1 panned on PrP or Superblock in round 2. Therefore, 




Figure 6.7. Phage panning round 1. To enrich phage particles which specifically 
recognize PrP, we panned phage particles from Figure 6.5C onto various conditions. 
We did not observe a difference between phage panned on PrP or the various negative 
controls (A). These data suggested a subsequent round of panning was required to 
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10-1 TMTC TMTC TMTC TMTC 
10-2 TMTC TMTC TMTC TMTC 
10-3 20 41 28 24 
10-4 3 3 1 3 
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Superblock	 PrP	 Superblock	+	PDL	 PrP	+	PDL	
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further enrich PrP-specific clones. We therefore grew up, precipitated, and titered phage 




Figure 6.8. Phage panning number 2 enriched specificity by an undefined amount. 
M13 helper phage amplified and precipitated from pan number 1 (Figure 6.7) was 
subsequently panned to enrich PrP-reactive clones.  The number of colonies reduced 
as expected after subsequent panning rounds (A). Strikingly, phage particles panned on 
PrP were highly specific to PrP because panning on superblock did not yield any 
colonies (A), and the culture lacked turbidity after overnight growth (B). However, the 
immune library did contain phage which recognizes Superblock, because phage panned 
on Superblock in round 1 continued to recognize Superblock in round 2.  
 
Master plate analysis. We infected TG1 cells with phage derived from the second round 
of phage panning (Figure 6.8) and allowed them to grow overnight. This overnight-
grown culture was homogenously spread across selective medium, and individual 
colonies were inoculated into a 96 well plate containing media (“master plate”).   Each 
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well (“clone”) was screened for nanobody insert via PCR with MP57 and GIII primers 
(Figure 6.9A). We observed 22 clones expressed the appropriately sized nanobody 
insert (Figure 6.9A), and periplasmic extract derived from these clones were assessed 
for PrP reactivity via ELISA. Four clones, A2, A9, B10, and B11, showed the highest 
reactivity with PrP (Figure 6.9B). Thus, we expressed and purified those nanobodies in 
BL21 cells to test using other biochemical techniques. However, the yield was lower 
than anticipated (Figure 6.9C). Therefore, future directions could involve transforming E. 
coli strain WK6 to generate higher quantities of soluble nanobody. 
 
 
Figure 6.9. Library master plate analysis. Individual clones were screened for true 
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Master plate clones which express true nanobody 
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B11, A12 








contain the appropriately sized nanobody insert. Periplasmic extract (1:5) from these 
clones were screened for PrP reactivity via ELISA (B). We chose the four highest-
reactive clones (blue boxes) to grow up, purify, (C) and screen via other biochemical 
techniques.  
 
CDR3 sequence analysis. Pardon et al. (2014) grouped clones from the same B cell 
lineage based on level of CDR3 homology. If two CDR3 regions are the same length 
and share over 80% homology, they likely derived from the same B cell lineage and 
thus likely recognize the same epitope.  We purified and sequenced plasmids from the 
10 clones which reacted to PrP (Figure 6.8B) and analyzed the CDR3 homology using 
Serial Cloner. Briefly, we translated the nanobody sequence and identified CDR3 amino 
acids by comparing the framework sequences obtained from Schoonaert et al. (2017). 
We then performed each pairwise comparison and attempted to group clones which 
arise from the same B cell lineage. Comparisons highlighted in orange fit the 
parameters outlined in Pardon et al. (2014). Comparisons highlighted in green (**) likely 
do arise from the same B cell lineage, although the framework identification may have 
been shifted by one amino acid. Importantly, certain comparisons (*) may show high 
homology even though only a few amino acids aligned with each other. These 






Figure 6.10. CDR3 sequence homology analysis. Pardon et al. (2014) defined clones 
with CDR3 sequences with 80%+ sequence homology and identical length to derive 
from the same B cell lineage and likely share epitope binding domains. These 
homologous comparisons are highlighted in orange. Alignments highlighted in green 
represent comparisons which likely share the same B cell lineage, but either had one 
deleted amino acid in the middle and/or contained one N or C terminal additional amino 
acid. Comparisons with asterisks (*) are above 80% homology, yet are not the same 
length. For example, a 100%* comparison could have one or two aligned amino acids in 
the middle, but the other amino acids are not homologous.  
 
 
Two clones may preferentially bind infectious brain homogenate. Based on periplasmic 
reactivity to recombinant PrP (Figure 6.9B), we selected four clones: A2, A9, B10, and 
B11 to make large batches of recombinant nanobodies in E. coli BL21 cells. We first 
A2 A9 A10 A12 B7 B8 B10 B11 C2 E10 
A2 85*	 77	 71	 71	 70	 63	 100*	 80	 85*	
A9 83	 71	 75	 79	 100*	 78	 100*	 100*	
A10 50	 100*	 67	 85**	 80*	 100*	 69	
A12 80*	 67	 50	 86*	 71	 100*	
B7 63	 100*	 50	 100*	 88*	
B8 67	 75	 67	 73	






tested reactivity to purified immunogen loaded via western blotting (Figure 6.11A), and 
indeed observe signal from all nanobodies tested. However, these nanobodies 
nonspecifically bind various brain proteins via western blotting (data not shown), and we 
did not observe signal in PK-treated samples, indicating these nanbodies either: do not 
recognize PrP in the PK-resistant core or they preferentially recognize 3D epitopes 
which are only revealed in non-denatured forms. Indeed, we provide evidence of the 
latter because we observe higher reactivity in brains which express PrP than in PrP KO 
brain via ELISA (Figure 6.11C).  
 
Surprisingly, however, we were unable to observe discernable difference in PrP signal 
via flow cytometry (Figure 6.11B). These data suggest either: these nanobodies do not 
recognize mouse prion protein, or perhaps they specifically recognize infectious prions. 
While we observed background signal in PrP KO brain via ELISA with most of the 
clones, we obtained promising data from clones A9 and B11. A9 appears to specifically 
recognize infected brain (RML5 or E2), and B11 appears to specifically recognize elk 
PrP, both from infected and non-infected brain. However, non-infected brains were 
homogenized with buffer containing Triton X-100 (NBH), whereas infected brains (RML5 
or E2) were homogenized in PBS only. Future directions should involve comparing 
infected to non-infected when the homogenates are prepared with the same buffers. 
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Figure 6.11. Two positive clones may specifically recognize infected brain. We 
chose clones A2, A9, B10, and B11 to purify and test for specificity. While all four clones 
recognize purified recombinant PrP from various species via western blotting (A), we 
observe little nanobody signal differences between wild type and PrP KO mouse brains 
via flow cytometry (B). However, A9 appears to preferentially bind infected brain (RML5: 
mouse-adapted scrapie; E2: chronic wasting disease isolate E2), and B11 appears to 




Nanobodies could function to delay prion disease in a number of ways. Nanobodies 
may bind prions and render them innocuous. For example, nanobodies could bind 
prions and prevent the PrPC:prion interaction. Alternatively, nanobodies could bind 
PrPC, perhaps promote internalization, and thus reduce prion substrate (PrPC) needed 
for propagation. However, future studies on whether nanobodies induce internalization 
are required. Lastly, similarly to Domanska et al. (2011), one could engineer 
nanobodies which bind domain(s) important for amyloidogenesis. Perhaps such a 
nanobody could bind PrPC and limit or prevent conversion to PrPSc. However, future 
studies are required to determine if nanobodies generated in this chapter prevent 
fibrillation. As discussed previously, PrPC spontaneously aggregates with shaking and 
low pH. One could incubate the enclosed nanobodies with PrPC under aggregation-
prone conditions and determine whether nanobodies limit the generation of PK-resistant 
aggregates. If so, translating these findings in vivo may limit or prevent the onset of 
prion disease.  
 
Recently, Ilijina et al (2017) reported nanobodies inhibit alpha-synuclein fibrillation. 
Specifically, incubating alpha-synuclein oligomers with two nanobody clones, NbSyn2 
and NbSyn87, resulted in fewer fibrils, as well as increased sensitivity to PK digestion. 
Perhaps nanobodies against both PrPC and infectious prions (similarly to clone B11), 
may prevent the PrPC:PrPSc interaction and thus delay or prevent prion propagation. We 
would also like to test the hypothesis nanobody clone A9 specifically recognizes 
infectious prions only. Testing differences (if any) between outcome after treatment with 
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A9 or B11 may help determine whether targeting PrPC or the misfolded form is most 
promising for combating prion disease. Previous studies suggest targeting PrPC, either 
transiently or permanently, could reduce the substrate needed for prion propagation and 
thus delay disease. However, these treatments would eliminate the normal function of 
PrPC as discussed in Chapter 5. For example, targeting PrPC may render a patient 
immunosuppressed. Therefore, we suggest targeting misfolded prions instead of PrPC. 
We believe nanobodies, such as clone A9, could provide such an avenue. Future 
directions could involve testing the capacity of B11 or A9 to prevent in vitro fibrillation 
and/or prion disease in vivo. 
 
The concept of prion strains emerged after Bessen and Marsh (1992) reported 
differential clinical outcomes after inoculation with transmissible mink encephalopathy 
(TME). The two prion strains, termed hyper (HY) or drowsy (DY) TME, are manifested 
with shorter incubation times and hyperactive behavior versus long incubation times and 
lethargic behavior, respectively. Further, work from the Telling lab suggests chronic 
wasting disease prions may exhibit strain-like behavior. Certain CWD prions exhibit 
differential histological patterns, such as bilateral or unilateral hemisphere deposition, 
yet exhibit nearly identical resistance to chemical denaturation (Angers et al. 2010). The 
strain phenomenon remains elusive. We hypothesize strains arise from different 
conformations of PrPSc. Therefore, one could utilize nanobodies to probe for 
conformational differences between prion strains. If so, one could use nanobodies to 




In summary, data presented in this chapter aimed to generate alpaca-derived 
nanobodies. These nanobodies may provide useful for understanding structural 
differences between prions, as well as potentially used to inhibit prion formation in vitro 
and in vivo. Future directions include epitope mapping, fibrillation assays with or without 
nanobodies, as well as testing whether these nanobodies limit or prevent prion 
propagation in vivo. With the ability to cross the BBB, we propose nanobodies are viable 
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Prions encipher disease information by structurally perverting native host protein. While 
prion researchers made great strides since Stanley Prusiner coined the term prion in 
1982, many questions remain unaddressed. For example: which host proteins facilitate 
disease transmission? What is the function of the properly-folded, cellular prion protein? 
Lastly, are there ways to combat prion disease? Data presented in this dissertation 
aimed to (at least partially) address these questions. Factor H (fH) limits autoimmunity 
by binding host proteins and preventing Complement deposition. In Chapter 2, we show 
fH binds misfolded prions and aids in disease transmission because fH-deficient mice 
propagate fewer prions in the lymphoreticular system and resist disease longer than 
their Factor H sufficient cohorts. These data suggest preventing the Factor H:prion 
interaction may prolong survival times. Likewise, we show in Chapters 3 and 4 
Complement protein C1q and receptors CD21/35 directly binds prion amyloid. 
Alternative splicing generates CD21 and CD35, and the relative importance of each 
splice variant in prion disease remained unknown. In Chapter 3, we provide evidence 
CD21 promotes prion disease more-so than CD35 and highlights specific cell-type roles 
in prion pathogenesis. Further, we show soluble CD21 may provide a therapeutic 
avenue to combat prion disease in vivo. Previous reports suggest C1q promotes 
scrapie, but we show an opposite trend in a CWD mouse model. However, human error 
and perhaps inappropriate comparisons limit the interpretations presented in Chapter 4. 
In Chapter 5, we assessed the role of the prion protein, PrPC, in eliciting adaptive 
immunity. We report B cell activation, from early events such as SRC phosphorylation 
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and calcium mobilization to antibody production partially relies on PrPC expression. 
Lastly, we generated an immune library from an alpaca vaccinated with recombinant 
prion protein in Chapter 6. After cloning the variable domain and generating ~15 kD 
nanobodies, initial screening suggests two clones may preferentially bind the misfolded 
form of PrP. Next steps include testing whether these nanobodies prevent prion 
infection in vitro and in vivo. Collectively, data presented in this dissertation not only 
highlight Factor H and CD21 as host proteins which promote prion disease, but also 
provide tools and reagents to potentially combat prion disease.  
